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Hand-Wrist Bone Age in Children Treated for Acute Lymphoblastic Leukemia
Abstract
Acute Lymphoblastic Leukemia (ALL) is the most common malignancy of childhood, constituting 31
percent of all childhood malignancies. Treatment strategies to target ALL include chemotherapeutic
agents, irradiation of the neck and/or spine, and bone marrow transplantation. The aggressive nature of
antineoplastic therapies often produces numerous craniofacial and dental sequelae as well as additional
harmful effects to the entire body. Cranial irradiation may adversely affect the hypothalamic-pituitary axis
decreasing growth hormone production. Consequently, children with ALL may experience a transient or
permanent reduction in growth iatrogenically. Hand-wrist radiographs are valuable for evaluating
maturational status in children with ALL. These radiographs allow for the comparison of a child’s
chronological age with relative “bone age.” OBJECTIVE: This study used hand-wrist radiographs to
determine the maturational status of children treated with ALL. Bone age was compared to the child’s
chronological age to determine the delayed, normal, or advanced tempo of growth. The null hypothesis
was that anti-neoplastic therapies have no discernible effect on a child’s tempo of bone maturation.
METHODS: Handwrist radiographs (n=108 films) of 73 children (39 boys, 34 girls) treated at St. Jude
Children’s Research Hospital for ALL were evaluated to assess “bone age.” Mean chronological age at
diagnosis was 4.54 years (sd = 2.81). The number of films per child was highly skewed, since most were
taken soon after the diagnosis of ALL (and, thus, close to the onset of treatment). Bone ages were scored
for each of the 73 patients based on Greulich and Pyle’s 1959 standards (GP2), specifically the atlas
method. RESULTS: We supposed that the combination of antimitotic drugs used to treat ALL would
discernibly depress the childrens’ tempos of growth, so that BA-CA (bone age-chronological age) would
become negative (and become larger during the course of treatment). We found no evidence of this in our
study. In fact, since there was no depression of the rate of maturation during treatment, there was no
need for a compensatory, or “catch-up,” phase. There was, then, no evidence that treatment for ALL had
any effect on the progress of hand-wrist bone age towards maturity. There also was no detectable effect
on the tempo of growth for those treated with cranial irradiation versus children with chemotherapy alone.
In conclusion, treatment for ALL spares the tempo of growth as measured by HW bone age. This is a
favorable outcome since treatment did not alter the duration of growth, so prognosis of normal adult
status is good. This finding accounts for several prior studies that reported normal adult body dimensions
(in the absence of radiation treatment) in subjects treated for ALL in childhood.

Document Type
Thesis

Degree Name
Master of Dental Science (MDS)

Program
Orthodontics

Research Advisor
Edward Harris, Ph.D.

Keywords
Acute Lymphoblastic Leukemia, Bone Age, Hand-Wrist Radiograph

Subject Categories
Diseases | Medicine and Health Sciences | Neoplasms
This thesis is available at UTHSC Digital Commons: https://dc.uthsc.edu/dissertations/161

HAND-WRIST BONE AGE IN CHILDREN TREATED FOR ACUTE
LYMPHOBLASTIC LEUKEMIA

A Thesis
Presented for
The Graduate Studies Council
The University of Tennessee
Health Science Center

In Partial Fulfillment
Of the Requirements for the Degree
Master of Dental Science
From The University of Tennessee

By
Mary Elizabeth Martin, D.D.S.
May 2006

Copyright © Mary Elizabeth Martin, 2006
All rights reserved

ACKNOWLEDGEMENTS

I would first like to thank Dr. Edward F. Harris for his constant
leadership through, not only my three years in orthodontics, but also my four
years of dental school at The University of Tennessee. Without his guidance and
perseverance, my thesis would not have been possible. I must also express my
sincere appreciation to Dr. Sue Kaste and Dr. Chris Rowland at St. Jude
Childrens’ Research Hospital for their direction. It is my hope that my thesis
will be among many more written as collaborations between St. Jude and The
University of Tennessee’s Orthodontic department. Lastly, I appreciate the time
and energy my committee members, Dr. William Parris, Dr. Quinton Robinson,
and Dr. Edward Harris have committed to helping me refine and complete my
thesis. Without their support, this project would not have been possible.
I would like to dedicate my thesis to both my family and my husband,
David. I first became interested in dentistry at a young age from simply
watching and admiring my father. I cannot express how fortunate I feel to have
been given the opportunity to follow in my father’s footsteps. The constant
support of my parents, my sister, and husband will always be my
encouragement and source of aspiration to be the best orthodontist and person
possible.

ABSTRACT

Acute Lymphoblastic Leukemia (ALL) is the most common malignancy of
childhood, constituting 31 percent of all childhood malignancies. Treatment
strategies to target ALL include chemotherapeutic agents, irradiation of the neck
and/or spine, and bone marrow transplantation. The aggressive nature of antineoplastic therapies often produces numerous craniofacial and dental sequelae
as well as additional harmful effects to the entire body. Cranial irradiation may
adversely affect the hypothalamic-pituitary axis decreasing growth hormone
production. Consequently, children with ALL may experience a transient or
permanent reduction in growth iatrogenically. Hand-wrist radiographs are
valuable for evaluating maturational status in children with ALL. These
radiographs allow for the comparison of a child’s chronological age with relative
“bone age.” OBJECTIVE: This study used hand-wrist radiographs to determine
the maturational status of children treated with ALL. Bone age was compared to
the child’s chronological age to determine the delayed, normal, or advanced
tempo of growth. The null hypothesis was that anti-neoplastic therapies have no
discernible effect on a child’s tempo of bone maturation. METHODS: Handwrist radiographs (n=108 films) of 73 children (39 boys, 34 girls) treated at St.
Jude Children’s Research Hospital for ALL were evaluated to assess “bone age.”
Mean chronological age at diagnosis was 4.54 years (sd = 2.81). The number of

films per child was highly skewed, since most were taken soon after the
diagnosis of ALL (and, thus, close to the onset of treatment). Bone ages were
scored for each of the 73 patients based on Greulich and Pyle’s 1959 standards
(GP2), specifically the atlas method.

RESULTS: We supposed that the

combination of antimitotic drugs used to treat ALL would discernibly depress
the childrens’ tempos of growth, so that BA-CA (bone age-chronological age)
would become negative (and become larger during the course of treatment). We
found no evidence of this in our study. In fact, since there was no depression of
the rate of maturation during treatment, there was no need for a compensatory,
or “catch-up,” phase. There was, then, no evidence that treatment for ALL had
any effect on the progress of hand-wrist bone age towards maturity. There also
was no detectable effect on the tempo of growth for those treated with cranial
irradiation versus children with chemotherapy alone. In conclusion, treatment
for ALL spares the tempo of growth as measured by HW bone age. This is a
favorable outcome since treatment did not alter the duration of growth, so
prognosis of normal adult status is good. This finding accounts for several prior
studies that reported normal adult body dimensions (in the absence of radiation
treatment) in subjects treated for ALL in childhood.
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CHAPTER I

INTRODUCTION

Acute Lymphoblastic Leukemia (ALL) constitutes 31 percent of all
childhood malignancies and now represents the most common malignancy of
childhood. ALL strikes children primarily between two and ten years of age.
However, it may also attack adolescents and adults. Higher rates of ALL have
been found among populations in North America, Northern and Western
Europe, and Oceania, whereas lower rates have been seen in Asian and African
populations. Though the cause of ALL is not known, several substances or
entities have been implicated to include: ionizing radiation, the used of drugs
and chemicals, as well as various viruses.
As cure rates for children with ALL approach 80 percent, this sample
provides an excellent means by which to examine anti-neoplastic treatment
influences on growth and development. Chemotherapy and radiation (of the
head and neck, as well as the spine) are commonly utilized in the treatment of
ALL.
As radiation and chemotherapeutic agents often fail to differentiate
between metabolically active normal cells and neoplastic cells, a patient’s overall
tempo of growth is often adversely affected. Growth and development describe

the changes an individual progresses through from conception until death.
Growth is defined as a change in physical size of the organism as a whole or any
of its parts. Development is defined as a change in proportion and/or an
increase in complexity. Development indicates not only a change in shape of the
entire body, but also individual anatomical structures.
Sonis et al. (1990) noted that an altered hypothalamic-pituitary function
may result in decreased growth hormone production. Hypopituitarism has been
shown to follow high-dose irradiation of both intra- or extracranial tumors (Tan
and Kunaratnam 1966; Shalet et al. 1975; Richards et al. 1976). Several studies
related the prevalence of diminished stature in children with ALL. However,
these studies failed to demonstrate a decrease in the overall tempo of growth.
Kirk et al. (1987) reported high rates of only diminished stature in children
treated for ALL, however overall growth retardation was not demonstrated.
Conversely, Clayton et al. (1998) concluded that while chemotherapy did
contribute significantly to diminished stature in children with ALL, mean loss in
the majority of children was not high enough to substantiate GH replacement
therapy.
Bones in the skeleton may be analyzed throughout an individual’s life—
from birth, through skeletal maturation, finalized with the end of life (Greulich
and Pyle 1959). Chronological age, or a person’s age in calendar years, serves as
the standard by which most laypersons gauge maturity. However, this

measurement often does not adequately reflect a person’s biological maturity or
development, particularly when considering those periods of infancy or
childhood. The framework or connective tissues of the body serve as a standard
applicable to general body development. Skeletal or biological age, also termed
“developmental age” and “physiological age,” reflects the level of maturity
achieved by the individual (Todd 1937). Average bone or skeletal ages, then,
illustrate the maturation status in which normal children, male and female,
match up with their corresponding calendar or chronological age (JimenezCastellanos et al. 1996).
Hand-wrist radiographs are commonly used in the assessment of
biological age because the hand and wrist are reasonably accessible and those
vital organs particularly at risk to radiation damage are not in close proximity.
A hand-wrist bone age serves as the measure by which a child’s chronological
age may be compared. The child’s developmental status may be shown as
delayed, normal, or advanced. Hand-wrist radiographs serve as an excellent
measure to determine the effects of anti-neoplastic therapy.
The present study analyzed the hand-wrist radiographs of 73 children
treated at St. Jude Children’s Research Hospital in Memphis, Tennessee for ALL.
The number of films per child was highly skewed, ranging from one to four per
child. The focus of bone age analysis centered on determining whether the

tempo of growth was retarded based on treatment with chemotherapy and/or
radiation.

CHAPTER II

REVIEW OF THE LITERATURE

Introduction
Acute Lymphocytic Leukemia (ALL)—also known as Acute Lymphatic,
Acute Lymphoblastic, or Acute Lymphogenous Leukemia—now represents the
most common malignancy of childhood, constituting 31 percent of all childhood
malignancies (Niemeyer and Sallan 1998; Berg et al. 2000). Figure 1 is a barchart
of the most common types of cancer in children under 15 years of age, with their
percentage of total cases (Mirro 2000). While ALL accounts for nearly 75 percent
of all leukemias in children, it accounts for less than one percent of all adult
malignancies (Perkins et al. 1997; Berg et al. 2000).
The earliest descriptions of leukemia in the clinical setting were made
independently by Bennett in Scotland and Virchow in Germany; each published
his discovery in 1845. Their observations were based on a number of autopsies
of patients with “enlarged spleens and purulent-appearing blood” in which
microscopic analysis revealed a marked increase of “colorless corpuscles.”
Bennett suggested that the etiology of the increased white blood cell counts was
due to inflammation, while Virchow preferred the term “weisses Blut,” or white
blood, that was later rephrased in Greek as “leukemia” (Perkins et al. 1997). The
foremost breakthrough in cellular identification of the leukemias took place in
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Fig. 1. Classes of cancer in children under 15 years of age,
expressed as the pecentage of total cases.
Source: Mirro J. Treatment options. In Steen RG and Mirro J.
Childhood cancer. Cambridge: Perseus Publishing, 2000, p 11-7.

1891, when Paul Ehrlich established differential methods of staining and further
categorized neutrophilic, eosinophilic, and basophilic granulocytes (Bennett
1990).
ALL strikes children primarily between two and ten years of age, with the
peak age between two and three years. However, it can also attack adolescents
and adults, with a substantial increase around 65 years of age (Berg et al. 2000).
Figure 2 depicts overall incidence statistics by race and sex (Pui 1999). A survey
by the Surveillance, Epidemiology, and End Results Program (SEER) showed
that the incidence of ALL in the United States increased from 2.7 to 3.3 cases per
100,000 children aged 0 to 14 years old during the years 1973 to 1995. Latinos
represent the highest rates of ALL for both boys and girls in the United States
(Pui 1999). Each year, around 2,000 to 2,500 new cases of ALL are diagnosed in
the United States (Niemeyer and Sallan 1998).
Significant geographic differences exist with regard to the incidence of
ALL. Higher rates of ALL have been found among populations in North
America, Northern and Western Europe, and Oceania, whereas lower rates have
been seen in Asian and African populations. The highest rates of ALL in
European males have been reported for Spain, whereas the highest rates for
European females have been reported for Denmark (Pui 1999).
The cause of ALL is not known, though several explanations for an
overall cause of leukemia have been explored. Numerous environmental factors
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Fig. 2. Age-specific incidences for ALL by race and sex.
Source: Pui CH. Acute lymphoblastic leukemia. In Lee GR.
Wintrobe’s clinical hematology. Baltimore: Williams & Wilkins,
1999, p 1141-53.
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have been examined, including ionizing radiation, the use of drugs and
chemicals, as well as various viruses. The incidence of leukemia was shown to
be elevated in persons exposed to nuclear weapons in Hiroshima and Nagasaki,
thus confirming the association between ionizing radiation and leukemia.
Several chemical substances, such as benzene, chloramphenicol, and
phenylbutazone, have also been linked to the disease. Additionally, several
debilitating viruses have shown associations with leukemia. These include a
statistical linkage of the Epstein-Barr virus with African Burkitt’s lymphoma, the
human T-cell leukemia-lymphoma virus I (HTLV-I) with adult T-cell leukemialymphoma (ATL), and the HTLV-II virus with atypical hairy-cell leukemia
(Perkins et al. 1997).

The Composition of Blood
ALL primarily targets lymphocytes in the bloodstream. A vital organ that
delivers hemoglobin, oxygen, and other essential nutrients, blood also
transports chemicals and hormones to various cells throughout the body. Blood
is comprised of a variety of proteins that aid in nutrition, bodily defense, and
hormonal regulation. Whole blood is composed primarily of three elements in a
clear protein-rich medium known as serum or plasma: red blood cells, platelets,
and white blood cells. Red blood cells represent roughly 45 percent of whole
blood, with plasma contributing an additional 55 percent, and white blood cells

and platelets making up slightly below one percent (Ball and Lelek 2003).
Hematopoiesis, the process of blood cell formation and development, is
distinguished by a steady turnover of cells and is carried out by stem cells in the
bone marrow (e.g., Bell and Hughes 1997). Bone marrow is a sponge-like, fatty
material found within the confines of most bones. Red bone marrow, the
marrow responsible for the production of blood cells, is found predominantly in
the pelvis, sternum, ribs, skull and vertebral bodies in adults—and more broadly
in children (e.g., Ball and Lelek 2003).
Blood cells are derived from pluripotent stem cells found in bone
marrow, and they possess the ability to differentiate into a single cell lineage.
Figure 3 delineates this stem cell hierarchy. The clinical manifestations of
leukemia would be expected to reflect the level at which the malignant
transformation took place (Mauer 1990).
Red blood cells, or erthyrocytes, have an average life span of 120days.
Morphologically, these cells are biconcave discs without nuclei. These cells
contain hemoglobin, an iron-rich protein that transports oxygen from the lungs to
tissues and organs throughout the body. The blood is also responsible for
carbon dioxide transport and elimination. A deficiency of red blood cells,
known as anemia, can result in fatigue and weakness, nausea, as well as an
increased temperature and pale discoloration of the skin. Anemia may be
induced by a number of biological events, including nutritional deficiency,
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Fig. 3. A scheme for blood cell derivation, differentiation, and
proliferation.
Source: Mauer AM. Clinical features of human leukemia. Baltimore:
Johns Hopkins University Press, 1990, p 1-7.
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hemorrhage, increased hemolysis, bone marrow transplants, infection, heredity
or an acquired deficit (e.g., Bell and Hughes 1997).
Platelets, which are proteins essential to the blood clotting process, are
also formed in the marrow and are descendents of megakaryocytes. These cells
have an approximate life span of 5 to 10 days. A deficiency of platelets can
result in spontaneous bleeding with blood loss into tissues and organs of the
body. Excessive bruising of the skin often is seen with platelet deficiencies (Ball
and Lelek 2003).
White blood cells, or leukocytes, are involved primarily in the host
defense against disease-producing bacteria and parasites. The three main types
of leukocytes―monocytes, granulocytes, and lymphocytes―fulfill separate and
unique roles in the defense process. Monocytes are highly efficient and effective
at recognizing and digesting foreign bodies (or antigens), and may also aid in
long-term defense through antigen presentation to T-lymphocytes. The fully
differentiated monocyte is referred to as a macrophage (e.g., Ball and Lelek 2003).
Granulocytes comprise neutrophils, basophils, and eosinophils.
Neutrophils constitute the vast majority of the granulocyte population and are
skilled at identifying and destroying bacteria and other harmful substances. As
neutrophils are crucial in the defense against bacterial and fungal infections,
suppression or absence of these cells leaves the body open to injury from
viruses, bacteria, or other harmful parasites. Basophils are responsible for the

release of histamine during inflammation, while eosinophils target parasites and
aid in the ingestion of an antigen-antibody compound (e.g., Ball and Lelek 2003).
Lymphocytes defend the lymphatic system and blood. The lymphatic
system is an extensive network of vessels interconnected with small masses of
lymphatic tissue termed lymph nodes. Lymph nodes lie along the network of
lymphatic vessels and cluster primarily in the pelvis, neck, abdomen, and
underarm. The spleen, which is located in the upper abdomen, the thymus,
which lies beneath the sternum, and the tonsils and adenoids, which reside in
the posterior throat, are also components of the lymphatic system. Tissue fluid
carried throughout the lymphatic system, or lymph, is typically clear and watery
in appearance, with the same consistency of blood plasma. The main functions
of the lymphatic system are: absorption and transport of fat from the intestine to
the venous system; formation of a defense mechanism for the entire body; and
drainage of tissue fluid; as well as collection and transport of lymph from the
tissue spaces to the venous system (Moore and Dalley 1999).
Lymphocytes are the second most numerous cells in the blood,
comprising 20 to 44 percent of adult blood cells. Lymphocytes develop from
multipotent hematopoietic stem cells that possess the means to mature into a
range of different kinds of blood cells. These stem cells develop in the bone
marrow and then differentiate into fully functional white blood cells. The
common lymphoid progenitor cell may progress into T lymphocytes (T cells) or

B lymphocytes (B cells). T cells mature in the thymus, while B cells develop in
the bone marrow (e.g., Bell and Hughes 1997).
Lymphocytes attack infection primarily through the production of
antibodies, which fight germs and other harmful bacteria present with an
infection. Upon presentation of specific antigenic stimuli, lymphocytes may
transform into immunologically competent cells. This transformation is marked
by an increase in size, due to an increase in RNA in the cytoplasm or DNA in the
nucleus (e.g., Bell and Hughes 1997).
Cancer most commonly involves anaplasia, or the loss of a normal pattern
of the growth of cells. Anaplasia is characterized by an increased variability in
the appearance of cells. Anaplastic growth is common to nearly all tumors,
benign or malignant. Furthermore, the degree of anaplasia may be important
establishing prognosis of a tumor (Steen 2000).
The exact cause of leukemia, while currently deemed idiopathic, may
arise from certain genetic events occurring at particular stages of stem cell
development. The type of leukemia may then be linked to the genetic event and
stem cell from which the flaw derived (e.g., Ball and Lelek 2003).

Four Major Types of Leukemia
Four major forms of leukemia are recognized: acute lymphocytic, acute
myelogenous, chronic lymphocytic, and chronic myelogenous. The term “acute”

refers to leukemias that have a rapid onset and are characterized by an increased
number of young cells. In contrast, the term “chronic” denotes a slower
progressing disease, involving more developed cancer cells. Acute leukemias
are most often fatal, while chronic leukemias follow longer courses of
development. Lymphocytic leukemia involves cells of lymphoid origin, while
myelogenous leukemia involves cells of myeloid origin (Ball and Lelek 2003). A
classification of leukemia subtypes is listed below (Mauer 1990).
I.

II.

III.
IV.

Acute
A. Lymphocytic
B. Nonlymphocytic
Chronic
A. Lymphocytic
B. Myeloproliferative disorders
1. Chronic myelocytic leukemia
2. Polycythemia rubra vera
3. Essential thrombocythemia
Myelodisplastic syndromes
Miscellaneous chronic leukemias
A. Hairy cell leukoplakia
B. Adult T-cell leukemia
C. Sézary syndrome
D. Tγ-cell leukemia

ALL may be separated into three groups dependently on the apparent
size of the constituent lymphoblasts. L1 lymphoblasts are relatively small and
exhibit uniform structure and size among abnormal lymphoblasts. L2
lymphoblasts are larger in size and exhibit more structural and size variation,
termed “structural heterogeneity.” L3 lymphoblasts are the largest in size and
contain large voids, termed vacuoles. The L3 subtype, referred to as “Burkitt’s

type” because of its morphological similiarities to Burkitt’s lymphoma, carries
the worst prognosis of all subtypes (Perkins et al. 1997).
The L1 subtype is prevalent in childhood ALL, occurring in roughly 85
percent of all cases. The L2 subtype is most common in older people, while the
L3 subtype represents only 1 to 2 percent of all ALL cases. These three subtypes
may be further divided based on relative B or T cell similarities, demonstrated
through a process called phenotyping. B lymphocyte lineage subtypes, which
account for approximately 85 percent of ALL cases, are noticed by isolating cell
surface markers on the leukemic blasts that match those of normal B
lymphocytes. T lymphocyte lineage subtypes, which account for approximately
15 percent of ALL cases, are noticed by isolating cell surface markers on the
leukemic blasts that match those of normal T lymphocytes. Detailed analysis of
an ALL case often identifies surface antigenic or molecular markers that may aid
in identification or classification of the specific disease type (Berg et al. 2000).

Acute Lymphoblastic Leukemia

Symptoms
Patients with ALL usually present with symptoms coincident with bone
marrow invasion and deterioration (Perkins et al. 1997). Most often, this spread
of leukemic cells is uncontrolled and extramedullary. The most common sites of

extramedullary ALL involvement are the central nervous system, lymph nodes,
testes, liver, kidney and spleen. The central nervous system (CNS) and the testes
often carry the highest clinical implications (Berg et al. 2000). Inherent anemia,
thrombocytopenia, and neutropenia, or the depletion of red blood cells, platelets,
and white blood cells, respectively, often manifest in signs of weakness and
debility. Bleeding problems often range from mild complications such as
petechiae, bruising, and mucosal bleeding, to severe problems such as GI
bleeding and CNS hemorrhage. Hepato-splenomegaly and lymphadenopathy
may also be noticed and attributed to lymphoblast engorgement (Perkins et al.
1997). Oral manifestations of ALL include swollen and bleeding gums, as well
as relative periodontal infections (Greene 2002). Approximately 40 percent of
childhood leukemia patients exhibit bone and joint manifestations, such as pain
or sensitivity. Numerous patients, as high as 25 percent, can present with
fractures or osteopenia most commonly of the long bones. These changes or
symptoms are usually seen in areas of accelerated growth and development,
such as the knees, wrist, and ankles. Niemeyer and Sallan (1998:1255) stated
these symptoms, “may be the result of direct leukemic infiltration of the
periosteum, periosteal elevation of underlying cortical disease, bone infarction,
or expansion of the marrow cavity by the leukemic cells.” Overall signs and
symptoms depend on a range of factors including age of onset, duration of
treatment, and subtype of ALL.

Prognosis
“Progress in the treatment of ALL has been incremental, beginning with
the development of effective therapy for CNS disease, followed by
intensification of early treatment” (Pui 1999:1141). Cure rates for children
currently are near 80 percent, while rates for adults approximate 30 to 40
percent. These high cure rates demonstrate the obvious progress that has been
made in the treatment of ALL (Pui 1999).

Treatment Strategies
The current high and improving survival rates of ALL and other forms of
cancer are due in large part to research efforts and improved treatment strategies
(Goho 1993). When considering the treatment course for a person with ALL,
physicians examine a number of factors: the ALL subtype, the composition of
previous treatments and its successes or failures, levels of leukemic cells in the
blood, the presence or absence of chromosomal aberrations, as well as the
patient’s age and overall health (Wells et al. 1983). Treatment modalities may
consequently differ significantly from person to person.
Many options exist for the treatment of acute lymphocytic leukemia.
These include chemotherapy, radiation, and bone marrow transplantation.
Physicians may use one therapy or combine methods to treat particular cases of

ALL. Multimodal therapy “creates synergistic and additive effects” not
normally gained from the utilization of one therapy only (Goho 1993).

Chemotherapy
Chemotherapy is the treatment currently chosen for most types of acute
leukemias. The first reported use of a chemical as an anti-neoplastic agent came
from experiments with nitrogen mustard in a person with Hodgkin’s disease in
1942. Six years later, the discovery of remission induction by antifolates in ALL
introduced chemotherapy as an anti-cancer agent. These chemotherapeutic
principles have led to curative therapies for the acute leukemias and
lymphomas, successful treatments for the chronic leukemias and multiple
myelomas, and have supplied the conceptual foundation for contemporary
medical oncology (Chabner et al. 1999).
As the malignant process is distinguished by uncontrolled cell
proliferation, it is understandable that chemotherapy should target DNA
replication (Chabner et al. 1999). Chemotherapeutic agents strive to prevent
cancer cells from invading, multiplying, metastasizing, and destroying the host
(Skeel and Khleif 2003). The majorities of efficient cancer agents either generate
chemical lesions in DNA or interfere with the synthesis of DNA. The ultimate
means by which cancer drugs produce cell death is uncertain. Destructive
mechanisms may range from apoptosis, or programmed cell death, to progression

of death following mitosis. “While most antimetabolites and alkylating agents
target DNA, other drugs attack the mitotic spindle (vinca alkyloids), inhibit
protein synthesis (L-asparaginase) or induce cell differentiation (all-trans-retinoic
acid)” (Chabner et al. 1999:186).
Chemotherapeutic drugs may be given orally, intravenously, or directly
into a muscle. These medicines are systemic, and they are able to move freely
through the bloodstream and body. Chemotherapeutic drugs are occasionally
injected into the spine to access cerebrospinal fluid in the brain and spinal cord;
this therapy is termed intrathecal chemotherapy (e.g., Mirro 2000).
The cell cycle of cancer cells is essentially that of normal cells. Figure 4
depicts not only the approximate time spent in each phase of the cycle, but also
the main function of each period (Skeel and Khleif 2003).
Chemotherapeutic drugs that target DNA may be classified as either
specific or nonspecific in reference to a phase of the cell cycle, and are ultimately
dependent upon their interference with the mitotic cell cycle. Figure 5 depicts
the dynamics of chemotherapeutic interferences within the cell cycle (Goho
1993). Specific agents disrupt DNA synthesis (S phase) or cell division (M
phase) (Goho 1993). Early treatments should comprise multi-drug
chemotherapeutic doses large enough to kill the majority of the leukemic cell
population. Agents commonly used in therapies are vincristine, prednisone,
doxorubicin, methotrexate, asparaginase, and intrathecal cytosine arabinoside
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(Berg et al. 2000). Table 1 lists various chemotherapeutic agents with their
associated clinical complications (Rodman and Reed 2000).
Nonspecific agents target cells in all phases of the functioning cell
cycle, with the exception of inactive cells in the G0 phase. These drugs crosslink
DNA bases to disrupt DNA replication. These agents include alkylators
(busulfan, chlorombucil, cyclophosphamide, melphalan, and nitrogen mustard),
nitrosureas (BCNU, CCNU), antibiotics (actinomycin D, doxorubicin), DTIC, and
cisplatin.
Since tumor cells replicate asynchronously, they are not all
in susceptible phases during the initial chemotherapy
exposure. Chemotherapeutic agents are eliminated rapidly,
and a single dose does not affect tumor cells entering a
susceptible phase at a later time. Furthermore, chemotherapy works on first order kinetics, in which only a
percentage of cells are killed with each dose, leaving some
undamaged cells. Chemotherapeutic agents are therefore
administered in multiple (fractionated) doses so that tumor
cells unaffected by the first dose are destroyed by following
doses [Goho 1993:7].
Figure 6 depicts the effects of multiple dose chemotherapy on cancer cell
numbers (Skeel and Khleif 2003).
As it aims to destroy cancer cells, chemotherapy often affects those
normal cells or bodily organs that are undergoing reproduction at accelerated
rates. Mucosal linings, such as those of the mouth and intestines, as well as the
skin, hair follicles and bone marrow, are often affected. The overall goal
involves selecting a chemotherapeutic agent that produces marked destruction

Table 1. Chemotherapy side effects.
Late and/or Delayed
Complications

Chemotherapy

Early Complications

L-asparaginase

Nausea and vomiting, allergic
reactions (such as rashes or
difficulty in breathing),
temporary diabetes, change in
mental status

Unknown

busulfan

Low blood counts; nausea,
vomiting, and diarrhea

Loss of normal menstrual
function; increased skin
pigmentation, lung
damage

carboplatin

Tiredness; low blood counts

Hearing problems; kidney
damage

cisplatin

Hearing loss; nausea, vomiting,
diarrhea; vein and tissue
damage if drug leaks from vein

Hearing problems; kidney
damage

cyclophosphamide Nausea and vomiting; bladder
damage; low blood counts;
fluid retention; hair loss

Bladder cancer or
secondary leukemia
(rare); decreased fertility

cytarabine

Nausea and vomiting; mouth
sores; low blood counts; fever;
skin rashes; irritated eyes;
seizures; diarrhea or liver
damage (from high-doses)

Decreased fertility

daunorubicin,
idarubicin,
doxorubicin,
epirubicin,

Nausea and vomiting; hair loss;
mouth sores; low blood counts
resulting in anemia, bleeding
or higher risk of infection; redcolored urine (not blood); skin
burn if drug leaks out of vein;
hair loss

Heart failure, skin or
tendon deformities;
pigmentation; secondary
cancer

Table 1. Continued
Late and/or Delayed
Complications

Chemotherapy

Early Complications

etoposide,
teniposide

Nausea and vomiting; hair loss; Secondary leukemia
mouth sores; low blood counts; (uncommon)
allergic reactions (wheezing,
difficulty in breathing, skin
rashes swelling of lip); low blood
pressure

hydroxyurea

Drowsiness; low blood counts;
increased pigmentation; hair
loss

ifosfamide

Hair loss; nausea and vomiting; Increased skin color;
bladder damage with bleeding; kidney damage
vein irritation; low blood
counts; confusion,
hallucinations

mercaptopurine

Nausea and vomiting; low
Unknown
blood counts; mouth sores; skin
rashes; liver damage

methotrexate

Nausea and vomiting; low
blood counts; mouth sores;
skin rashes

Seizures, intellectual
impairment; kidney
damage (from high-dose
treatment); liver damage

prednisone,
prednisolone,
dexamethasone

Temporary diabetes, high
blood pressure, changes in
mood or behavior, acne;
increased appetite; weight
gain; peptic ulcer; muscle
weakness

Decreased growth;
decreased bone density;
joint destruction

Secondary cancer

Table 1. Continued
Chemotherapy

Early Complications

Late and/or Delayed
Complications

thioguanine

Low blood counts; liver
damage

Loss of normal menstrual
function

thiotepa

Pain at injection site; low blood
counts; dizziness; fever; hair
loss

Secondary leukemia

topotecan,
irinotecan

Diarrhea; low blood counts

Unknown

vincristine,
vinblastine

Constipation; weakness;
numbness or loss of reflexes;
skin burn if drug leaks out of
vein; seizures; hair loss

Skin or tendon
deformities

Source: Rodman J, Reed W. Chemotherapy. In Steen RG, Mirro J. Childhood
cancer. Cambridge: Perseus Publishing, 2000, p 141-51.
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of cancer cells, while providing minimal damage to normal cells (e.g., Skeel and
Khleif 2003).
Side effects of chemotherapeutic therapy range in severity among patients
with ALL. As healthy marrow cells are destroyed along with tumor cells,
various bleeding problems associated with diminished platelet counts, as well as
anemia and infection may ensue. Therapeutic action on the intestines and their
linings often induce nausea and vomiting as common side effects of ALL. Other
symptoms of chemotherapy may include anaphylaxis, stomatitis as well as other
oral complications, xerostomia, hair loss (alopecia), diarrhea, constipation, and/or
an altered nutritional status due to a direct insult on the gastrointestinal tract
(Tipton 2003).
Of particular importance to the dental profession are the symptoms of
chemotherapy specific to the oral environment. Many of the drugs used in
cancer therapies are cytotoxic to the oral mucosa, interfering specifically with the
replication, growth, and maturation of epithelial cells. These toxic effects are
expressed clinically by reduction, denudation, and ulceration of the mucosa
surface. Immunosuppressive actions of chemotherapeutic agents cause the host
to be particularly susceptible to bacterial, fungal, viral, and mixed infections.
Myelosuppressive actions of these agents can trigger neutropenia and
lymphocytopenia, or severe decreases in blood neutrophils and lymphocytes.
The most common sites of oral infections are the lips and tongue, followed by

the buccal mucosa, gingiva, palate, oropharynx, and occasionally the major
salivary glands (Dreizen and Brown 1983).

Radiation
Among the oldest and most efficient of cancer treatments, radiation
therapy was recognized over a century ago for its ability to destroy both
cancerous and healthy tissues (Merchant 2000). Radiation therapy targets cancer
cells while trying to avoid damaging normal tissues or organs (e.g., Goho 1993).
However, cells and structures lying within the radiation beam can be injured as
well. While affecting rapidly dividing cancer cells more than normal cells,
radiation therapy often also damages rapidly dividing healthy cells. Skin and
hair are the tissues most noticeably affected by radiation treatment, which can
also result in skin lesions, burning, redness, and possible hair loss (Greene 2002).
Dentofacially, radiation can affect bone growth, including “microvascular injury,
fibrous replacement of marrow spaces, osteocyte death, and periosteal damage”
(Kaste et al. 1994:95).
Radiation may originate from either an internal or external source:
external radiation produces deep penetrating gamma and X-ray photons, while
internal radioisotopes generate gamma and X-ray photons and beta particles.
These beta particles impair DNA and amino acids either directly by ionizing

critical structural molecules or indirectly by first ionizing intracellular water
used by the cells for vital processes (Goho 1993).
The ultimate effect of radiation therapy on an active tumor cell depends
on its position in the cell cycle during therapy. Cancer cells in the M, G1, and G2
phases of the cell cycle are actively involved in mitosis and often sustain the
most damage from radiation. All cancer cells, even those in the G0 resting phase,
may be affected by high doses of radiation. Figure 5 depicts the effects of
radiation, as well as chemotherapy reviewed above, on cells at various stages of
the cell cycle (Goho 1993).
Radiation treatment also may be used to decrease tumor size, provide
palliative therapy, or treat inoperable malignancies. Therapy may be
multimodal, through a combination of substances or involve a single agent.
Commonly used radioactive agents include, but are not limited to: Cesium
(Cs137), Cobalt (Co60), Iodine (I131), Phosphorus (P32), Gold (Au198), Iridium (Ir192),
Yttrium (Y90), and Palladium (Pa109) (Howard 2002).
Effects of radiation therapy vary immensely, but depend on the area of
the body being irradiated as well as the schedule and dose of therapy. Side
effects may be either short-term, occurring within the first 90 days after
treatment initiation, or long-term, occurring after the initial 90 days. Short-term
effects may include tissue destruction similar to a burn, discoloration of the skin,
and/or weakness. Long-term effects may include tissue atrophy, scarring,

impaired growth, as well as cancers secondary to initial diagnosis (Merchant
2000).

Bone Marrow Transplantation
Bone marrow transplantation (BMT), a newer type of therapy, can be
used in conjunction with chemotherapy to enhance eradication of cancer cells.
BMT therapy begins with considerable doses of chemotherapeutic agents (with
or without radiation) to eliminate the bone marrow in the patient’s body.
Healthy stem cells are then provided by a donor (allogeneic BMT) or harvested
from the patient’s own marrow (autologous BMT). A third type of transplant, a
syngeneic BMT, involves an identical twin as a donor. The healthy marrow is
then supplied to the patient intravenously, with the new marrow intended to
replace the diseased marrow (Horwitz 2000).
Significant research is being devoted to the newer forms of BMTs, namely
autologous transplants. After being removed from the patient’s body, the
diseased marrow is treated with chemotherapeutic agents aimed at destroying
cancer cells. The treated marrow is then frozen to ensure preservation. The
patient then undergoes chemotherapy to kill all remaining cancer cells not
removed in the marrow harvest. The bone marrow transplant is concluded with
the treated marrow intravenously placed back into the patient (Horwitz 2000).

Progression of Treatment
Treatment for ALL, though largely dependent on the mode of therapy,
age of onset, and subtype of the disease, often progresses through four main
phases: (1) Remission induction therapy, the initial phase, uses
chemotherapeutic agents to destroy a maximum number of leukemic cells while
minimizing the “residual leukemic burden” (total number of leukemic cells in
the body). (2) Consolidation or intensification therapy, the second phase, is
used once the patient exhibits no sign of cancer and is in remission. This phase
consists of large doses of chemotherapy to destroy remaining cancer cells. (3)
Central nervous system (CNS) prophylaxis, the third phase, is often combined
with consolidation-intensification therapy. This phase involves high dose
therapy to both eliminate cancer cells in the CNS and prevent their spread to the
spinal cord or brain. Radiation therapy may or may not be used. (4)
Maintenance therapy, the fourth and final phase, spans the course of several
years and exists solely to preserve remission of the disease (Silverman et al.
1995).

Treatment Effects on the Human Body

Effects on the Dentition and Oral Mucosa
Multimodal cancer therapy for pediatric head and neck tumors may be
associated with significant developmental orofacial abnormalities (Berkowitz et
al. 1989). Aggressive anti-neoplastic therapies, specifically chemotherapy and
radiation often present significant detriment to the health and quality of life of
long-term survivors of ALL (e.g., Kaste et al. 1997). As cure rates continue to rise,
dentofacial complications from various therapies become increasingly relevant
(Goho 1993).
The dental sequelae in patients treated for ALL are not surprising,
because permanent teeth are undergoing active development during childhood,
which is the time of peak incidence of ALL. Human dentitions, both primary
and secondary, begin their development early in life (e.g., Arey 1965; Corliss
1976). The primary dentition commences at approximately 6 weeks of gestation
and maintains growth through three years of age, at which point the roots have
completely formed (Kraus and Jordan 1965; Lunt and Law 1974). The
permanent dentition reaches its peak growth between the ages of four and six.
Illness, trauma, chemotherapy, and radiation therapy may each affect
dental development at any point prior to complete maturation. The timing of
the insult within the process of dental development is important. An

understanding of these dentofacial changes and exploration of their causes is
essential so that suitable diagnosis and treatment, as well as future prophylaxis
may be well planned. Still, because several therapies and agents are employed
in a single patient’s treatment, the task of attributing a single dental abnormality
to one specific agent or therapy is often impossible (Goho 1993).
Sonis et al. (1990) stated that current ALL treatments in children often
produced developmental disturbances of the craniofacial skeleton and
permanent dentition. The severity and degree of these disruptions depended on
the child’s age at onset of ALL, dose of cranial radiation, and central nervous
system treatment. Children receiving treatment prior to five years of age had
the most severe dental defects, indicating that developing, immature teeth might
be at an increased risk for developmental disturbances compared to mature teeth
(Sonis et al. 1990).
Kaste et al. (1997) reported increased frequencies of hypodontia,
microdontia, overretention of primary teeth, rampant decay, root stunting and
taurodontism among the effects of ALL treatment. Additionally, Goho (1993)
confirmed chemoradiation’s connection to congenital tooth agenesis, precocious
apical closure, and coronal hypocalcification, in addition to microdontia and root
shortening.
Kaste et al. (1997) evaluated the panoramic radiographs and clinical
records of 423 ALL survivors to quantify the incidence, distribution, and

potential predisposing factors for dental abnormalities due to treatment for ALL.
The following abnormalities were recorded during systematic examination of
the panoramic radiographs: root stunting, microdontia, hypodontia,
taurodontia, and over-retention of the primary teeth.
Hypodontia, or the incomplete development of a full complement of 32
permanent teeth, was noted in some children in a study by Kaste et al. (1997).
Microdontia, the development of abnormally small teeth, occurred in about 20
percent of this sample. While fairly rare in the general population, microdontia
of maxillary lateral incisors and of third molars occurred in nearly five percent of
the ALL sample. Kaste et al. (1997:795) stated:
Hypodontia and microdontia can cause abnormal spacing
and drifting of teeth, potentially resulting in poor dental
alignment, malocclusion, and dysfunction of the
temporomandibular joint. In addition, hypodontia or root
stunting preclude adequate orthodontic anchorage and place
these teeth at added risk for the damaging effects of gingival
and periodontal disease.
Over-retention of primary teeth, the failure to shed primary teeth in a
timely manner, occurred in roughly four percent of the sample. Over-retention
of primary teeth involves not only the problem of retaining a primary tooth, but
also the delayed eruption of the succedaneous tooth. Though controversial
whether over-retention is due to chemoradiation, this abnormality is often
associated with the following systemic conditions: Down syndrome,
hypopituitarism, and hypothyroidism (Kaste et al. 1997). Goho (1993) reviewed

the overall effects of chemotherapy and radiation treatments and stated that any
factor (or treatment modality) affecting dental development might also influence
the relative progression of the ensuing teeth.
Extensive carious lesions present as frequent dental anomalies in children
treated for cancer. Kaste et al. (1998) evaluated a retrospective sample treated for
neuroblastoma, and noted that many of these patients had inadequate oral
hygiene habits and increased carbohydrate intakes. Kaste et al. (1998:24) stated:
Dietary factors and parent permissiveness may also
contribute to the increased dental caries in pediatric
oncology patients.
Frequently these children develop
stomatitis and oral mucosal ulcerations. They may prefer
sweet foods, thereby further promoting tooth decay.
Medically compromised patients often require high
carbohydrate diets in order to maintain caloric intake.
Extremely ill patients may not feel well enough to concentrate on their
oral health. Additionally, young children depend on their parents for oral
hygiene maintenance. Oral health and prophylactic care should be a chief
priority when addressing treatment concerns for oncology patients (Kaste et al.
1998). It is necessary to have a comprehensive understanding of the patient’s
medical status as well as any plans for cancer treatment.
Root stunting, though rare in the general population, occurred in nearly
25 percent of the same sample evaluated by Kaste et al. (1997). The most
frequently affected teeth, the molars, were supposed to most frequently sustain
damage because of their developmental status at the early age of treatment. As

the roots of the permanent molars had not developed fully before treatment was
initiated, they were more frequently and severely affected by oncotherapy. In
contrast, development of the permanent incisors, premolars, canines, and
crowns of molars was nearly complete by the time treatment begun in most
patients (Kaste et al. 1997).
Taurodontism, the presence of noticeably wider and lengthened pulp
chambers, can occur in either the primary or permanent dentitions (Pindborg
1970). This anomaly is most often attributed to a “delay in the development and
proper positioning of Hertwig’s epithelial root sheath after formation of the
tooth crown resulting in the apical displacement of the pulpal floor and
furcation areas” (Llamas and Jimenez-Planas 1993). Llamas and Jimenez-Planas
(1993) suggest that genetic factors might affect the timely development of
Hertwig’s root sheath in cases of nontreatment-related taurodontism.
Commonly found in only one to 11 percent of the general population,
taurodontism was identified in approximately 17 percent of the study. Within
the sample exhibiting taurodontism, 98 percent were under the age of eight
years old leading the researchers to speculate that cancer therapy in young
patients might promote taurodontism. Clinically, teeth exhibiting taurodontism
have markedly decreased root surface, are more susceptible to periodontal
disease, and are less agreeable to orthodontic treatment (Kaste et al. 1997).

Root agenesis, or early apical closure, may be attributed to radiation
therapy. While it represents a form of systemic therapy, chemotherapy would
not simply affect one tooth class; instead, it would affect whichever teeth are
undergoing crown-root formation. Goho (1993) reported a patient in whom
early apical closure of the roots of the first and second molars correlated with
root development at 4.0 to 4.5 years old, the age at which the child began antineoplastic therapy.

Effects of Radiation on the Head and Neck
The processes of enamel formation, amelogenesis, and the process of dentin
formation, dentinogenesis, are affected by radiation directed at or near the mouth.
Orofacial structures, including the teeth and mucosa, receive approximately half
the radiation when located near the exposure, while radiation directed at distant
structures provides no damage to the developing dentition (Goho 1993). Figure
7 depicts radiation therapy fields commonly used in the treatment of head and
neck cancers (Berkowitz et al. 1989). In the past, when dentofacial damage was
anticipated, physicians commonly provided bilateral radiation to balance facial
skeletal growth disturbances and preclude hemifacial hypoplasias (Goho 1993).
Nwoku and Koch (1995) suggest that while the skin and mucosa are sensitive to
radiation, both show extensive regenerative power, which probably explains
why bone seems to suffer more injury than the epidermis.

Fig. 7. Common radiation fields used in the treatment of cancers of the head.

Source: Berkowitz RJ, Neuman P, Spalding P, Novak L, Strandjord S, Coccia PF.
Developmental orofacial deficits associated with multimodal cancer therapy:
case report. Ped Dent 1989;11:227-31.
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Overall damage depends on the dose delivered, regardless of the
therapeutic means employed. Sonis et al. (1990) mentioned doses of 2,000 to
4,000 cGy in both animals and humans have been shown to induce tooth and
root “dwarfism,” root foreshortening, hypoplasia, microdontia, and atypical root
morphology. Prior to morphodifferentiation and mineralization, radiation
treatments may result in arrest of the developing dental tissues. Equally, at later
stages of development, dental malformations or arrested development have
been observed (Sonis et al. 1990). Low doses of radiation may cause little or no
damage to developing ameloblasts and odontoblasts, while high doses induce
rapid cell death. Radiation affects cells in all stages of the cell cycle, whether
proliferating or not. Dental development in humans has been revealed to
sustain localized damage at 400R. However, the dose at which odontogenic cell
death occurs unequivocally is still unknown (Goho 1993).

Effects of Chemotherapy on the Head and Neck
Chemotherapeutic effects depend on both the dose and the repetition of
drugs. While radiation therapy affects cells in all stages of the cell cycle,
chemotherapy only impacts actively dividing cells. Additionally, while
radiation therapy damages only those cells in its path, chemotherapy is more
extensive in its effects. Chemotherapy not only harms cells near or inside a
tumor, it also affects cells and organs located far from the desired sites. The

following results of chemotherapeutic treatments have been documented:
enamel defects, obstructed root development, and reduced dentin formation.
Goho (1993) stated that eruption rates have shown no detrimental effects from
chemotherapy.
Chemotherapeutic agents exhibit short half-lives and are eliminated
quickly from the bloodstream. Consequently, effects on odontoblastic cells can
be fatal, but are most often merely harmful (Goho 1993).

Endocrinologic Complications
As radiation and chemotherapeutic agents often fail to differentiate
between metabolically active cells and neoplastic cells, numerous dental and
craniofacial abnormalities have resulted from such anti-neoplastic treatments.
However, Sonis et al. (1990) noted that an altered hypothalamic-pituitary
function may result in decreased growth hormone production. Consequently,
odontogenesis and craniofacial development might be adversely affected (Sonis
et al. 1990).
When considering acute lymphoblastic leukemia, factors commonly
affecting growth may include chemotherapy, irradiation, infection, poor
nutrition, or the actual disease itself. “Cranial irradiation, leading to growth
hormone (GH) deficiency, has been implicated as the main etiological agent in
growth retardation following the treatment of brain tumors” (Clayton et al.

1988:460). Previous growth studies of ALL indicated that GH replacement
therapy to be needed only when chemotherapeutic dose levels exceeded 2,4002,500 cGy (Clayton et al. 1998).
Hypopituitarism has been shown to follow high-dose irradiation of both
intra- or extracranial tumors (Tan and Kunaratnam 1966; Shalet et al. 1975;
Richards et al. 1976). Smaller doses of cranial irradiation are often used in ALL,
with hopes that these children sustain no considerable effects to the
hypothalamic-pituitary axis. However, Schiliro et al. (1976) and Shalet et al.
(1976) reported that these children may be at an increased risk of growth
hormone (GH) deficiency, with their ultimate response in proportion to the
“dose and fractionation of the irradiation” (Swinft et al. 1978:890). Additionally,
Shalet et al. (1976) reported there may possibly be a progressive drop in GH
response with increasing time after cranial irradiation. Interestingly, Kirk et al.
(1987) noted that “idiopathic” GH deficiencies occur more commonly in males,
so perhaps the male hypothalamus is more vulnerable to other abnormalities of
GH regulation (1987;192). Lawrence et al. (1971:893) stated,
The site of radiation damage to the hypothalamic-pituitary
axis is unknown. The pituitary is generally considered to be
relatively radioresistant, probably because histological
pituitary cell necrosis is rarely seen after irradiation. Radiotherapy may however alter pituitary cell function, increase
permeability of the blood-brain barrier to potentially
encephalotoxic drugs or damage the vasculoglial tissues of
the hypothalamic-pituitary axis affecting the synthesis and
release of hypothalamic releasing hormones.

Kirk et al. (1987) reported high rates of only diminished stature in children
treated for ALL, however overall growth retardation was not demonstrated.
Stature had decreased by more than one standard deviation in 32 percent of
survivors at 4 years post-diagnosis and in 71 percent at 6 years post-diagnosis.
Standard deviation scores were constructed as deviation measurements from the
population mean. Kirk et al. (1987) also mentioned growth of younger children
and those children especially tall for their age at diagnosis were more
susceptible to reductions in overall stature.
Clayton et al. (1998) also evaluated changes in stature. 82 children treated
for ALL were evaluated who achieved complete and continuous first remission
following cessation of treatment. Forty-eight children received prophylactic
cranial irradiation at a total dose of 1,800 cGy and 38 children received a dose of
over 2,000 cGy. Chemotherapy spanned two to three years, with both groups of
children showing a comparable decrease in height standard deviation. The
greatest decrease in height occurred within the first year of diagnosis, whereas,
height standard deviation scores of both groups increased significantly upon the
completion of treatment. Clayton et al. (1998) concluded that while
chemotherapy did contribute significantly to diminished stature in children with
ALL, mean loss in the majority of children was not high enough to substantiate
GH replacement therapy.

Swinft et al. (1978) noted the importance of a regular review of not only
the neoplastic condition, but also detailed surveillance of growth and
development. Endocrine investigation is essential only if growth and
development are cause for concern.

Clinical Effects and Prophylactic Care
Orthodontic tooth movement, prosthetic replacement of missing teeth,
periodontal health, endodontic procedures, and prophylactic home care may be
compromised after therapies in children treated for ALL . The achievement of
optimal dental health is increased if the clinician is mindful of dental
development at the time of treatment as well as the type and quantity of
treatment delivered (Goho 1993).
A panoramic radiograph, at minimum, should be obtained prior the
beginning anti-neoplastic treatments. This radiograph enables clinicians to
locate potentially vulnerable dental structures and establish a baseline of oral
health specific to that patient. An additional panoramic radiograph should be
obtained at the conclusion of treatment. This radiograph details damage to
dental structures, allows for quantification of its severity, as well as aiding in an
overall treatment approach to restore dental health (Goho 1993).
The prognosis for the correction of craniofacial abnormalities caused by
anti-neoplastic therapies is guarded. Clinicians are often unable to formulate an

ideal treatment plan for these patients. Quite often then, treatment is
compromised at the beginning. Sonis et al. (1990:2651) reported problems
specific to mandibular growth potential:
Moreover, mandibular growth remains retarded, leaving
patients with a skeletal disharmony between the two jaws.
Conventional orthodontic correction of these problems often
relies upon mandibular growth, although an attempt is
made to retard maxillary growth therapeutically, allowing
the mandible to “catch up” to the maxilla. Because the
mandibles of our patients lacked intrinsic growth potential,
correction may only be achieved with orthognathic surgery.

Human Growth and Development
Growth and development describe the changes an individual progresses
through from conception until death. Growth is defined as a change in physical
size of the organism as a whole or any of its parts. Examples of such growth
may be an increase in height, an increase in weight, or an increase in arch
circumference. Growth is not necessarily an increase, but may denote a decrease
in size such as formation of the digits of the hand through selective cell death
(apoptosis). When considering neoplastic conditions such as ALL, “growth is a
sensitive measure of a child’s health and would thus be assumed to be affected
in these children for multiple reasons: severe disease, irradiation of the skull,
cytostatic treatment and perhaps poor nutrition” (Berglund et al. 1985:530).
Development is defined as a change in proportion and/or an increase in
complexity. One such example includes the progression of fine motor skills and

dexterity throughout life. Development indicates not only a change in shape of
the entire body, but also individual anatomical structures.
Growth of the postnatal individual may be divided into four major
intervals: infancy, childhood, adolescence, and adulthood. Each interval is
distinguished by its own characteristic rate of growth. Figure 8 depicts velocity
of growth for these four intervals of growth (Tanner 1962).

Scammon’s Growth Curves
Richard Scammon (1927) described four main patterns of postnatal
growth. These four patterns, known as the “Scammon Curves” and
diagrammed in Figure 9, are: general (or somatic), neural, lymphoid, and
genital. These curves assume birth as the starting point (= 0%) and 20 years of
age as “maximal adult dimensions and size” (= 100%).
The general or “somatic” pattern of growth represents growth of the body
as a whole and encompasses such measurements as height, weight, et cetera.
This pattern has been divided into four parts: (1) a period of rapid growth in
infancy at 0 to 5 years of age; (2) fairly uniform increments during early and
middle childhood at 5 to 11 years of age; (3) a rapid parapubertal increase at 11
to 16 years of age; and (4) a final period of slower growth during late
adolescence and early childhood at 16 to about 35 years of age.

Growth per Unit of Time

Peak
Height
Pre-Pubertal Velocity
Minimum

Infant
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Juvenile Phase
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Adult
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Fig. 8. Human growth velocity chart for somatic tissues partitioned into
the four major intervals of postnatal growth. (Drawing provided by Dr.
E. F. Harris.)
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Fig. 9. Scammon’s four tissue-specific patterns of postnatal growth. The scheme
is that size is standardized to 0% of adult size at birth and 100% of adult size
occurs by 20 years of age. (Drawing provided by Dr. E. F. Harris.)
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Tissues reflecting the neural pattern of growth include the brain and
associated structures (cerebellum, pons, and medulla), the eyeball and the pineal
gland. The two parts of the neural growth curve are: (1) a period of rapid
growth subsequent to birth at 0 to 5 years of age; (2) a period of slow growth
leading into maturity from age 6 forward. The human brain has achieved
approximately 95 percent of its growth by age 7 or 8.
The lymphoid pattern of growth involves the weights of the thymus,
adenoids, tonsils, mesenteric lymph nodes, as well as the number of Peyer’s
patches in the small intestine and lymphoid follicles in the appendix. The three
parts of the lymphoid curve are: (1) a rise of greater velocity in infancy and early
childhood to an apex at puberty at 0 to 11 years of age; (2) a decrease in size from
late childhood to adulthood at 12 to 20 years of age; and (3) maintenance of
small size during adulthood commencing at age 20. Quite commonly the second
phase fails to occur; that is, lymphoid tissues such as the adenoids and tonsils do
not decrease adequately in size. This failure often presents problems for
orthodontists and pediatric dentists, as these children may develop habits of
mouth breathing which may adversely affect the dentition and related skeletal
structures.
The genital pattern of growth encompasses the testis, ovary, epididymus,
uterine tube, prostate, and seminal vesicles. The three parts of the this curve are:
(1) a slow rise in infancy followed by a latent period at 0 to 13 years of age; (2) a

rapid increase from the prepubertal period, through adolescence into early
maturity at 13 to 20 years of age; and (3) an extended period of maintenance
throughout adulthood beginning at age 20. The rapid rise in the genital curve
represents the increase various sex hormones which produce “sexual maturity”
in both males and females.

Intervals of Human Growth
The many diverse tissues and structures of the human body have
extremely different patterns of growth, as is illustrated by Scammon’s four
growth patterns. Cells of organs, as well as the organ as a whole, are highly
dependent on their environment for nutrient supply and removal. Organs may
appear particularly vulnerable during stages of increased or important growth,
such as rapid cell proliferation. These times of greatest vulnerability are termed
critical periods. Critical periods are those times in a tissue’s life during which the
opportunity for irreversible damage are greatest (Smith 1977).
The development of a particular organ or structure progresses through
four distinct stages depicted in Figure 10. This figure is representative of total
DNA and total protein content throughout life. These stages are: (a)
hyperplasia, (b) a mixed period of hyperplasia (multiplicative growth) and
hypertrophy (dimensional growth), (c) hypertrophy, and (d) maturity and aging.
The most critical period of growth corresponds with the hyperplastic phase, in

Differentiation
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Subcritical
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Degrowth
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Protein

Hyperplasia
Alone

Hyperplasia
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Hypertrophy
Alone

Maturity
& Aging

Fig. 10. Stages of development in the growth and differentiation of an organ
tissue. (Figure provided by Dr. E.F. Harris.)
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which cells are mostly rapidly proliferating. The interval of hyperplasia and
hypertrophy represents a “sub-critical” period.
As Scammon’s growth curves illustrate, the various different tissues and
organs of the body develop and mature at various rates. Thus, these different
structures possess separate critical periods and periods of maximum
vulnerability. Figure 11 depicts the critical period for several major organs of the
body.

Physiologic Age Assessments
Bones in the skeleton may be analyzed throughout an individual’s life—
from birth, through skeletal maturation, finalized with the end of life (Greulich
and Pyle 1959). “Maturational status can have considerable impact on diagnosis,
treatment goals, treatment planning, and the eventual outcome of orthodontic
treatment“ (Moore et al. 1990:33). Chronological age, or a person’s age in calendar
years, serves as the standard by which most laypersons gauge maturity.
However, this measurement often does not adequately reflect a person’s
biological maturity or developmental status, particularly when considering
those periods of infancy or childhood. The majority of children may be seen as
“average maturers,” with a strong association between their chronological and
biological ages. Some children, however, may appear developmentally delayed,
and these are termed “late maturers.” Conversely, “early maturers” is the term

Brain

Skeleton
males

Muscle

Adipose
Fetal Life

Infancy

?
Childhood

Adolescence

Fig. 11. Critical periods for major organs and tissue systems. (Figure
provided by Dr. E.F. Harris.)

53

that describes those children whose developmental growth precedes their
chronological age (Tanner 1962).
The framework or connective tissues of the body serve as a standard
applicable to general bodily development. The skeleton has been chosen in the
past merely because radiographic technique provides “a ready, easily applicable
and noninjurious method of determination. Skeletal age thus becomes a
measure of bodily maturation and not a goal in itself” (Todd 1937:13). Skeletal
or biological age, also termed “developmental age” and “physiological age,”
reflects the level of maturity achieved by the individual. While a number of
methods exist by which biological age may be assessed, two provide particular
information to the dental profession. These methods are a “bone age”
evaluation based on hand-wrist radiographic analysis and a “dental age” based
on formation of the crowns and roots of developing teeth as seen
radiographically (e.g., Demirjian 1978).
Average bone or skeletal ages illustrate the maturation status in which
normal children, male and female, match up with their corresponding calendar
or chronological age (Jimenez-Castellanos et al. 1996). Similar to the growth of
organs in the human body, bones of the skeleton progress through their
morphological development at different points in time. In the child, new
(secondary) ossification centers appear over a span of time, and existing ones are

remodeled. Knowing initiation times and morphological changes of bones in the
hand and wrist provide a means of relating skeletal age to chronological age.
The following excerpt was taken from Greulich and Pyle’s text,
Radiographic Atlas of Skeletal Development of the Hand and Wrist:
The development of individual bones of the hand and wrist
as well as those of other regions can be impaired by febrile
and other illnesses and they seem to be especially vulnerable
to such deleterious influences at certain stages of their
differentiation. A hand-wrist film made of such a child
before the affected ossification center or centers have made
up their developmental deficiencies reveals the skeletal
imbalance that the illness has produced. The hand-film can
provide a record of past illnesses and a measure of the
severity of their impact on the developing skeleton, a
reflection of their impact on the total organism. Knowing
the rate at which these skeletal deficiencies are corrected, as
determined by subsequent X-ray examinations, is helpful in
appraising the child’s progress toward complete recovery
[Greulich and Pyle 1959:18].
Hand-wrist radiographs are commonly used in the assessment of
biological age because (1) the hand and wrist are reasonably accessible, (2) those
vital organs particularly at risk to radiation damage are not in close proximity,
(3) there are several bones (19 diaphyseal bones, 8 carpals, plus the distal radius
and ulna) by which developmental maturity may be measured. Technique
involves placing the hand directly on an X-ray cassette, with fingers spread
slightly apart. Source-to-film distance should be at least five feet. Figure 12
depicts the bones of the hand-wrist complex.
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Fig. 12. Schematic of the hand-wrist bones as visualized on a dorsoventral
radiograph. (Diagram provided by Dr. E. F. Harris.)

Development of Hand-Wrist Standards
Sydney Rowland was the first to mention use of hand-wrist radiographs
in children (cited in Pyle et al. 1971). Rowland used radiographs to formulate
indicators of skeletal maturity and published his description of the “shadows of
the hand bones of a nine year old girl” on April 2, 1896. Just four months earlier,
in late 1895, the scientific community had been introduced to the discovery of Xrays by the physicist Wilhelm C. Röentgen (Pyle et al. 1971).
A total of 29 bones exist in the hand-wrist complex by which a
physiological age assessment may be made. Nineteen phalanges are
present in the hand, three in each of the four fingers (proximal, middle, and
distal), while only two exist in the thumb (proximal and distal). Each ray has
one metacarpal, while the wrist has eight carpals. Each diaphysis has a
corresponding epiphysis on the distal end of each metacarpal and the proximal
end of each phalange. Thus, 21 epiphyses plus 8 carpals lends a total of 29 bones
available for evaluation in a hand-wrist film.
In 1929, under the direction of T. Wingate Todd of Case Western
Reserve University School of Medicine, the Brush Foundation began work
on preliminary human growth and development studies. When the study
began, there were no provisional standards by which to compare measurements.
The project commenced in 1931, with three-month-old infants enrolled in the

study, and concluded in the summer of 1942. The children, ranged in age from
three months to fourteen years (Greulich and Pyle 1959).
The children accepted for study were selected on the basis of
their freedom from gross physical or mental defects on the
promise of their parents to permit their continued
participation until the completion of the project. Since, in
addition, they were admitted only on application of a
pediatrician, their families were somewhat above average in
economic and educational status. All the children were
White, all had been born in the United States, and almost all
were of North European ancestry [Greulich and Pyle
1959:xii].
Children in the study were observed at three-month intervals during their
first year after birth, at six-month intervals from twelve months to five years of
age, and once a year thereafter. The series, published by Todd in 1937 as his
Atlas of Skeletal Maturation of the Hand, included from two to twenty-one handwrist films made at consecutive examinations of each of 1,000 children. While it
included information gathered from children in the Brush study, Todd also
incorporated films that he and his associates had made of other children from
various agencies and schools throughout the Cleveland, Ohio area (Greulich and
Pyle 1959).
Greulich and Pyle undertook the task of updating and extending their
own radiographic norms for skeletal age of adolescent males and females. Their
work, first published in 1950, was based on the 1930’s work of T. Wingate Todd
at Case Western Reserve University. When preparing their standards for
skeletal age in their second edition, Greulich and Pyle (1959) included not only

Todd’s X-ray films through 1936, but also those which were obtained during the
subsequent six years of the Brush study. Greulich and Pyle’s study arranged
substantial groups of children chronologically to provide measurements they felt
best represented children of that age. Their atlas differed from Todd’s in that it
included fewer standards. “It is our opinion, that, after the age of five years, in
both boys and girls, the skeletal development of the hand does not proceed
rapidly enough to require standards at more frequent than approximately
annual intervals except about the time of puberty” (Greulich and Pyle 1959:xiii).
Figure 13 depicts an example of a hand wrist film used in assessment of skeletal
age (Greulich and Pyle 1959).
Greulich and Pyle’s radiographic assessment of the hand-wrist complex
involved two specific steps, the atlas and the bone specific methods. The atlas
method involved comparing a hand-wrist film with the standard of the same sex
and nearest chronological age. The film would then be compared with adjacent
standards, both older and younger than the one is of the nearest chronological
age. Finally, the standard which appears most closely to resemble the film in
question is chosen. This first method is termed the atlas method (Greulich and
Pyle 1959).
After selecting the appropriate GP2 standard via the atlas method, the
examiner should proceed to make a more detailed comparison of the individual
bones and epiphyses visible in them. The bones of the hand-wrist complex

Fig. 13. Example of a dorsopalmar hand-wrist radiograph. The fingers are
relaxed. The radius is to the right (lateral) in this view. This particular example
if of a 6 year-old American white boy. All of the epiphyses are mineralized,
though that of the ulna is still small and sesamoid-shape. Seven of the eight
carpals are evident; the pisiform, if forming, is superimposed to the palmar
(anterior) of the triangular bone. (Figure provided by Dr. E. F. Harris.)
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should be considered in a regular order. That is, one should begin at the distal
ends of the radius and ulna, proceed next to the carpals, then to the metacarpals,
and finally to the phalanges. Similarly, one should examine the carpals in a
regular sequence—in their usual order: Capitate, Hamate, Triquetral, Lunate,
Scaphoid, Trapezium, Trapezoid, Pisiform. This method is termed the bonespecific method (Greulich and Pyle 1959).
If an individual bone in the film to be assessed is in
the same stage of development as the corresponding bone in
the standard selected for the detailed comparison, it should
be given the skeletal age that has been assigned to that bone
in that standard. If it appears to be either less advanced or
more advanced that its counterpart in that standard, it
should be compared with the same bone in its adjacent
standards. The proper skeletal age to be assigned to it is
that which is given in the standard to the corresponding
bone that shows the same degree of development. If none is
found that corresponds exactly in developmental status
with the bone to be assessed, its skeletal age should be
estimated from that of those which it most closely
resembles.
The developmental status of all bones of the hand to
be assessed will occasionally correspond exactly to that of
some one hand standard in this Atlas. When such is the
case, the skeletal age of that standard is the skeletal age to be
assigned to the child’s hand. If, however, its developmental
status does not correspond exactly to that of any one
standard but is, rather, intermediate between those of two
adjacent standards, the age assigned to the film should be
correspondingly intermediate between the ages of the two
standards which it most closely resembles [Greulich and
Pyle 1959:35-36].
In search of a standard appropriate for an independent study, Alice M.
Waterhouse and Tavia Gordon (1963) found that S. Idell Pyle was preparing a

reference standard that included the hand-wrist complex. Her standards were
based on the films of children enrolled in two growth studies conducted
independently from 1929 to 1962 by the Brush Foundation of Cleveland, Ohio,
and the Department of Maternal and Child Health in the Harvard School of
Public Health in Boston, Massachusetts (Pyle et al. 1971). These standards for the
hand and wrist were more complete chronologically than any other standard
currently in use in 1964. Standards were arranged evenly at six-month intervals
from ages three to thirteen years, and closely resembled the original standards
set by T. Wingate Todd in 1937. The key difference was that Todd’s atlas
included two separate series of films and age equivalents, one for males and one
for females. Thus, in 1962, at the urging of Drs. W. W. Greulich and H. C. Stuart,
Dr. Pyle was employed to prepare a single series of films that would provide
standards for both sexes [as long as bone age equivalents for each sex were
assigned to each bone.] Dr. Pyle’s study was included in the National Health
Survey, and was supported by the National Center for Health Statistics (Pyle et
al. 1971).
In constructing their standards for hand-wrist bone ages, Pyle et al.
proposed two objectives: (1) to select representative films that would offer a
variety of discernible features of developing hand-wrist bones—a series spaced
at three, six, or twelve month, and (2) to relate these structures as accurately as

possible to the chronological level at which they usually appeared in the median
position for the Cleveland boys and girls (Pyle et al. 1971).
Tanner et al. formulated two successive methods of estimating HW bone
ages that were believed to be “more flexible and deriving from a more solid
mathematical base than the Greulich-Pyle method” (1975:v). The first analysis,
named TW1, was published in 1962 and the second analysis, labeled TW2, was
published in 1975. The TW2 analysis was a follow-up to Tanner, Whitehouse,
and Healy’s 1962 analysis in which “each bone of the hand and wrist was
classified separately into one of eight or nine stages, to which scores were
assigned”(Tanner et al. 1975:v). These scores were then added to provide the
skeletal maturity estimate. The ordinal scale for rating the distal radius is
depicted in Figure 14. Grade A represents the appearance of the diaphysis
before any radiographic formation of the epiphysis is detectible. Grade B
corresponds to the initial development of an ossification center in the
cartilaginous precursor. Grades B through I depict progressive maturation and
development of the epiphysis, ultimately ending with its capping and fusion
with the diaphysis. Growth is completed at fusion, with the exception of minor
remodeling that can occur at the subchondral articular surfaces. The TW2
analysis formulated by Tanner et al. was a revised version of the TW1 (Tanner et
al. 1975).
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Fig. 14. The eight-grade ordinal scale of maturation of the distal radius.
Source: Tanner JM, Whitehouse RH, Marshall WA, Healy MJR, Goldstein H.
Assessment of skeletal maturity and prediction of adult height (TW2). New
York: Academic Press, 1975.
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Fishman also formulated a scheme for assessing HW bone age that was
published in 1982. His analysis was based on and involved a simplified
approach to Greulich and Pyle’s 1959 standards (GP2 standards). He noted both
the importance of hand-wrist films in measuring bone age and affirmed their
clinical importance in applications relating to dentofacial diagnosis and therapy.
He proposed four phases of bone maturation, located at six sites on the thumb,
third finger, fifth finger, and radius. These sites are the adductor sesamoid of
the thumb, the distal, middle and proximal phalanges of ray three, the middle
phalanx of ray five, and the epiphysis on the distal end of the radius.
Fishman’s assessment is based on 11 grades of maturity, and these are
depicted in Figure 15 as a flow chart by which the patient’s stage of
development is reached. The following excerpt was taken from Pyle et
al.’s A Radiographic Standard of Reference (1971:26):
The natural process of ossification begins in and spreads
from specific sites in each bone, namely, its growth centers.
Each expanding osseous mass in a cortex is surrounded by a
vital, expanding cartilaginous ‘rim’ which is always
differentiating ahead of the ossifying area until the bone
attains its adult shape and size. Accordingly, all skeletal
maturity indicators are preformed in cartilage. Since the
cartilaginous portion of any cortex is translucent to X-rays,
the entire growing bone is not shown in a radiograph.
Biological maturity is of importance to the dental profession. While
average maturing children represent the norm, the clinician should recognize
those children particularly late or early in their development. That is, those
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Fig. 15. Fishman’s 11-grade scheme used to assess skeletal maturity
from a hand-wrist radiograph. (Diagram provided by Dr. E. F.
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children fall outside the norms when their biological and chronological ages do
not correspond. Additionally, certain dental treatments, particular orthodontics,
often rely heavily on the individual’s growth potentials.

Effects on Human Growth and Development
With improved cure rates for acute lymphoblastic leukemia
(ALL) and the increasing number of long-term survivors, it
is important to determine whether clinically meaningful
growth retardation occurs in these children and whether
this adverse outcome is predictable and potentially
preventable [Schriock et al. 1991:400].

Stature and Weight
Anti-neoplastic therapies have been evaluated for their effects on the
overall tempo growth and development. Various research endeavors focused on
the effects on bone age, while other studies concentrated on therapeutic effects
on stature and weight.
Sklar et al. (1993) analyzed changes in height due to cranial irradiation for
127 children (68 females, 59 males) treated for ALL. Three treatment groups
were studied: 38 patients who received no cranial irradiation, 36 patients who
received cranial irradiation of 1,800 cGy, and 53 patients who received
irradiation of 2,400 cGy. Mean age at diagnosis of the patients was 6.4 years (sd
= 0.25 years). Results of the study indicated a significant overall decrease in
height standard deviation scores (SDS) for all three treatment groups from
diagnosis until the end of therapy and from the end of therapy until a final

evaluation. Patients in the 2,400 cGy treatment group had the greatest decrease
in height SDS, followed by those patients in the 1,800 cGy group. Those patients
who did not receive irradiation showed the least reduction in height SDS. Sklar
et al. (1993) mentioned that younger age and female sex were closely associated
with a significant decrease in height SDS for irradiated patients. A mean loss in
height SDS nearly twice that seen for others with similar dose treatment was
observed in female patients < 4 years of age at diagnosis. Growth hormone
replacement therapy was not recommended by these authors for most ALL
patients. However, female patients less than 4 years old were shown to be at
high risk of sustaining growth retardation (Sklar et al. 1993). Dalton et al. (2003)
proposed that an earlier onset of puberty in females might improve height at the
time of puberty because of acceleration in the rate of growth, but then might
compromise final height by decreasing the time interval for growth.
Katz et al. (1993) evaluated final adult height of 109 patients treated for
acute lymphoblastic leukemia between 1974 and 1981. Fifty-eight patients
received no cranial irradiation, while 51 received 2,400 cGy of cranial irradiation.
Prior to treatment, both groups had height distributions similar to those of the
U.S. population. Mean age of the patients at diagnosis was 7.8 years (sd = 4.2
years). Final examination of the 51 patients who received cranial irradiation in
addition to chemotherapy showed a mean height standard deviation score of 1.04, which corresponded to a median height reduction of 6.3 cm in females and

7.0 cm in males. In contrast, the 58 patients who did not receive cranial
irradiation achieved final heights coincident with those of the U.S. population.
In other words, this study found cranial irradiation to be significantly associated
with short stature in adults, but that their sample treated with chemotherapy
alone did not exhibit any long-term deficit.
“Obesity and short stature are commonly observed late effects of therapy
for childhood acute lymphoblastic leukemia” (Dalton et al. 2003:2953). Dalton et
al. evaluated the long-term effects of ALL treatment on height and weight for
618 children treated between 1987 and 1995 (2003). Three treatment groups were
studied: intrathecal therapy alone, intrathecal therapy with conventional cranial
irradiation, and intrathecal therapy with irradiation twice a day. Height and
weight values were recorded at diagnosis and every six months thereafter.
Body-mass index scores (BMI) were also calculated for each patient. Results
showed that children younger than 13 years of age experienced a greater
decrease in height and an increase in BMI compared with their older
counterparts. Cranial irradiation was not shown to be an influencing factor. An
increased chemotherapeutic intensity, as well as younger age, was significant
risk factors for greater growth retardation. No statistically significant difference
was seen in final heights between the irradiated groups and those who received
no irradiation. Dalton et al. found that final height was compromised in ALL
patients and further contributed to a relative increase in weight. They proposed

rather that as “patients became overweight for height; this seemed to be a result
of relative height loss with normal weight gain rather than accelerated weight
gain.” Additionally Dalton et al. (2003) suggested that subsequent weight gain
could be due to corticosteroid therapy, as was suggested by Van-DongenMelman et al. (1995).

Precocious Puberty
As treatment of childhood acute lymphoblastic leukemia is now largely
curing with the majority of children surviving into adulthood, there has been an
increasing concern regarding the effects of therapy on reproductive potential
and gonadal function in these children. Precocious or premature puberty,
defined as “pubertal development beginning more than 2 SD before the mean
age of the onset of puberty in the community,” has been reported after acute
lymphoblastic leukemia (Quigley et al. 1989:143). Pubertal development
commencing before 9 years of age in girls and 10 years of age in boys may be
considered precocious (Quigley et al. 1989).
Quigley et al. examined pubertal status and plasma levels of various
hormones in 45 children (20 girls and 25 boys) who had received combination
chemotherapy with 24 cGy of irradiation to the cranium. Hormonal levels of sex
steroids, as well as gonadotropin and inhibin, were assessed. Germ-cell damage
(specified by increased plasma levels of follicle-stimulating hormone) was

apparent in both sexes. These findings were confirmed in the boys by the
“absence of germ cells in the testicular biopsy specimens and by the small size of
the testes for pubic-hair stage” (Quigley et al. 1989). Furthermore, plasma
inhibin levels were measurable in only 44 percent of the pubertal girls, as
compared with over 93 percent of normal pubertal girls. Despite evidence of
apparent gonadal damage, the girls had an early menarche at a mean age of
11.95 (sd = 0.91) years, as compared with the Australian standard of 12.98 (sd =
1.11) years. Quigley et al. (1989) concluded that treatment for ALL may
contribute to gonadal damage in both sexes; however, puberty will occur at a
normal age or earlier in girls. Similarly, Greulich and Pyle (1959:8) stated that
“in precocious puberty, the gonadal and related hormones are present
abnormally early in quantities sufficient to cause the epiphyses of the various
long bones to fuse before growth has continued long enough to permit the
attainment of full normal adult stature.”
Brauner et al. (1984) remarked that gonadotropin deficiency can occur and
prevent or disturb pubertal development. Brauner et al. evaluated 29 children
with medulloblastoma (n = 14), head and neck tumors (n = 10), or acute
lymphoblastic leukemia (n = 5) who had received cranial irradiation before
seven years of age. These children were followed until the normal age of
puberty. Six children (5 girls and 1 boy) had precocious puberty, with puberty
beginning two months to 2.6 years after irradiation in the girls and after seven

years in the boy. One of these six children was a female who had been treated
for ALL. Her therapy began at six years of age with a cranial irradiation dose of
2,400 Rad. Precocious puberty commenced at 7.5 years of age. Additionally, the
child exhibited a relative growth hormone deficiency. None of the patients
examined had invasive hypothalmic lesions, hydrocephalus, or increased
intracranial pressure. Therefore, it was concluded that the precocious puberty
can be considered a consequence of cranial (and hypothalamic and pituitary)
irradiation (Brauner et al. 1984).

Treatment Influences on Bone Mass
ALL patients often experience impaired GH secretion following treatment
with cranial irradiation. This GH decrease has been associated with a reduced
bone mineral content. Similarly, long-term corticosteroid and methotrexate
therapy has also been linked to reduced bone mass. Nysom et al. (2001) studied
bone mass in 95 patients in first remission of ALL. Mean whole-body bone
mineral content (BMC) and bone mineral density area (BMDA), both useful
variables to predict the risk of fracture, were both decreased significantly
posttreatment. “Reduced bone mass several years after childhood ALL appears
to be caused by both reduced bone size and reduced size-adjusted bone mass”
(Nysom et al. 1998:3757).

Regarding bone mass after childhood ALL, Atkinson et al. (1989) found
reduced BMDA in the radius of 16 children 8 months after completion of
treatment. The leukemia process was implicated as the underlying cause of
reduced bone mass. The study later reported that bone mass was not
significantly reduced at the diagnosis of childhood ALL (Atkinson et al. 1990).
Vertebral fractures and osteoporosis may well occur in children with
newly diagnosed ALL (Newman et al. 1973; Samuda et al. 1987). In the past,
these injuries were the result of infiltration and extension of leukemic tissues;
however, they could also be an indirect result from a product of the malignant
cells. Prostaglandin E, ectopic parathyroid hormone, and osteoblast inhibiting
factor have been associated with the pathogenesis of bone loss (Newman et al.
1973; Samuda et al. 1987).
Gilsanz et al. (1990) also researched potential cases of osteoporosis in 42
patients treated for childhood ALL. The study utilized “quantitative computed
tomography, a technique that accurately measures trabecular vertebral bone
density, to establish or exclude the presence of osteoporosis in pediatric
patients” (Gilsanz et al. 1990:238). Patients who had received cranial irradiation
had significantly lower bone density than did untreated children in the normal
population. Thus, the authors concluded that overall loss of bone density did
not result from the disease or chemotherapy, but rather from the cranial
irradiation (Gilsanz 1990).

Chapter Overview
This Review of the Literature provides an overview of Acute
Lymphoblastic leukemia, including its numerous symptoms and treatments.
Effort was made to mention iatrogenic effects of such anti-neoplastic therapies,
as well as identifying radiographic methods to evaluate such harmful effects.
Acute Lymphoblastic Leukemia (ALL) represents the most common
malignancy of childhood, comprising approximately 31 percent of all childhood
malignancies (Niemeyer and Sallan 1998; Berg et al. 2000). Each year in the
United States, around 2,000 to 2,500 new cases are diagnosed, with ALL
predominately striking children between the ages of two and ten years
(Niemeyer and Sallan 1998; Berg et al. 2000).
ALL attacks the immune system by invading the blood and bone marrow;
however, metastasis is often seen in extramedullary sites such as the central
nervous system, lymph nodes, and spleen. Symptoms of ALL commonly
include anemia with inherent weakness and debility and joint pain, as well as
specific oral manifestations such as swollen and bleeding gums, as well as
periodontal infections.
Anti-neoplastic therapies often fail to differentiate between metabolically
active and neoplastic cells. Consequently, treatment effects may often harm
healthy tissues iatrogenically. Oral manifestations may include overretention of

primary teeth and delayed eruption of permanent teeth, as well as rampant
decay, microdontia, and root stunting.
Numerous methods have been reviewed by which an individual’s
skeletal growth and bone age may be assessed. Bone age, in contrast to an
individual’s chronological age, may properly reflect skeletal growth and
development. Due to reasonable accessibility and the availability of numerous
bones for evaluating maturity, hand-wrist radiographs are commonly used in
the evaluation of bone age. Hand-wrist radiograph analyses were proposed by
Greulich and Pyle in 1952, Tanner in 1975, and Fishman in 1982.
Treatment for ALL may also affect an individual’s overall growth and
development. Cranial irradiation had been shown to affect stature and weight;
height or stature is retarded, while weight centiles typically increase.
Individuals may also experience precocious puberty, or early-onset puberty
(defined as commencing at least two years before the mean onset of puberty in
the general population). Finally, treatment for ALL most often impairs growth
hormone secretion. Consequently, children often experience reduced bone mass
as well as fractures related to osteoporosis.

CHAPTER III

MATERIALS AND METHODS

Patient records were provided by St. Jude Children’s Research Hospital in
Memphis, Tennessee. Institutional Review Board (IRB) approval was granted
through both the University of Tennessee Health Science Center and St. Jude
Children’s Research Hospital (XPD04-022). Cases were selected based on a
diagnosis of acute lymphoblastic leukemia.
The data manager at St. Jude supplied a list of patients meeting a number
of predetermined criteria. The following data for each patient were entered into
an Excel spreadsheet: date of birth, diagnosis date, sex, initial examination date,
treatment protocols in addition to dates, and GP2 bone ages for all available
hand-wrist films. From these data, the following information was derived:
chronological ages, hand-wrist bone ages, and relative tempo of growth (as
delayed, normal or advanced). Overall demographics for the sample were as
follows:
(1)

All subjects had an initial diagnosis of acute lymphoblastic leukemia
(ALL).

(2)

This cohort of children was born no earlier than 1980 and no later than
2000.

(3)

Subjects had an ALL diagnosis date no earlier than 1985 and no later than
2003.

(4)

All subjects had at least one hand-wrist radiograph.

(5)

All subjects had a chronological age no older than 12 years old at initial
diagnosis.
We chose not to eliminate patients based on nationality. Our sample

represents a multicultural analysis of bone age in children with ALL. Children
in our study had been brought to St. Jude from throughout the United States and
various foreign countries. The majority of these children were white children of
European extraction.
Subjects were treated according to one of two protocols, either exclusive
chemotherapy or chemotherapy combined with cranial radiation.

Sample Characteristics
ALL is a disease that characteristically strikes young children as shown in
Figure 16. This graph plots the age distribution of the patients studied here, by
sex, and the median age at diagnosis is around four years of age for both sexes.
There were 73 children in this study (39 boys, 34 girls), each
represented by at least on hand-wrist film. The number of films per child was
highly skewed, though, since most films were taken soon after the diagnosis of
ALL (and, thus, close to the onset of treatment). Of these 73 children, 53 had just
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one hand-wrist film, 10 had two films, 5 had three films, and 5 had four films.
The total number of HW films was 108.
Mean chronological age at diagnosis was 4.54 years (sd = 2.81), with a
range of 0.10 up to 11.02 years of age. Age at diagnosis did not differ between
girls and boys (P = 0.15 by t-test).

Collection of Hand-Wrist Bone Ages
The focus of the bone age analysis centered on determining whether the
tempo of growth in the patients with ALL was retarded based on treatment with
chemotherapy and/or radiation. Bone ages were collected for each of the 73
patients based on Greulich and Pyle’s 1959 standards (GP2). All of the patients’
bone ages were assessed according to the GP2 atlas method, not the bone-specific
method. We necessarily assumed that the GP2 standards were appropriate for
our sample of predominately Caucasian children.
Bone ages were entered as decimal ages into a Microsoft Excel
spreadsheet (Microsoft Corporation version 11.2). For example, a patient would
be entered with a bone age of 11.5 years, but also a bone age of 138 months.
Similarly, patients’ chronological ages were also calculated in decimal ages.
Data collected in the Excel file were imported into the JMP 5.0.2 statistical
package (SAS Institute, Cary, NC). Following exploratory data analysis and
verifying extreme values, routine descriptive statistics were calculated, with the

tempo of growth (BA-minus-CA) being the key measure. This is a mixed
longitudinal study, but most of the data are tightly clustered near the onset of
treatment. Consequently, while we made as much use as possible of the more
informative repeated measures format of some of the data (with pairing design
tests and model II ANOVA) sample sizes were critically small. More power was
obtained from treating the data cross-sectionally, in which cases factorial
ANOVA models were used. Methods are described in Rosner (2000). All of the
tests were evaluated as two-tail at the conventional alpha level of 0.05.

CHAPTER IV

RESULTS

The purpose in this section was to test whether the treatment for ALL
(chemotherapy and/or irradiation) significantly altered bone age. Specifically,
bone age (BA) was evaluated for each child in this study using the Greulich-Pyle
sex-specific standards from their second edition (Greulich and Pyle, 1959),
commonly abbreviated as GP2. The central question was whether BA was
depressed relative to chronological age (CA) as treatment progressed.
Our expectation was that the treatment of children with ALL using very
potent drugs (with or without irradiation) would depress their tempos of
growth, at least transiently. The hypothesized scenario is sketched in Figure 17.
Because of the rapid onset of ALL, we expected that bone age at diagnosis would
not have had an opportunity to become delayed relative to CA. Our supposition
was that the sample of children would have bone ages equivalent to their CA
because: (A) we supposed that children who subsequently contract ALL are
growing normally, as a group, and (B) similarly, ALL is an acute-onset disease
that is not known to affect BA prior to onset. Also, we supposed that the GP2
sex-specific bone standards (Greulich and Pyle 1959)—which are the only
standards available (excepting those of the Tanner et al. 1975) are appropriate to

HW Bone Age

C

B

A
Chronological Age

Fig. 17. Diagrammatic sketch of the author’s hypothesized relationships
between CA and BA in children with ALL. The horizontal axis is chronological
age, the vertical axis is bone age, and the origin is the onset of treatment for
ALL. During phase “A,”soon after diagnosis, BA should be coincident with
CA. We supposed that treatment would depress BA during phase “B,” but
that there would be a recovery (compensatory) phase (”C”) after the
completion of treatment.
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this geographically heterogeneous sample of children with ALL. (Since we did
not have access to the HW radiographs, it was not possible to evaluate the GP2
bone-specific standards or the TWII standards).
As sketched in Figure 17, we anticipated that BA would be equivalent to
CA at the start of treatment within statistical limits. Specifically, we tested
whether BA-CA differed statistically from zero. In fact, it is different. At
diagnosis (we selected those HW BA readings taken within 1.0 year of
diagnosis), BA is significantly delayed, at least in boys. There are no HW films
prior to the onset of ALL, so we used those radiographs taken soon after the
onset of ALL as being representative of these children’s baseline status. For
girls, there was a sample of only 7 which yielded a test statistic of 0.1 and an
associated P-value of 0.95 (two-tail). The average difference between BA and CA
was 0.03 years (sd = 1.14). In boys, with a more informative sample size of 12,
the t-test was 3.2 with an associated P-value of 0.0081 (two-tail). The average
difference between BA and CA for these 12 boys was -0.71 (sd = 0.77) years.
Half of the boys (6/12) had bone ages equal to or greater than the CA, but those
with negative BA-CA differences ranged up to -2 years, and 4 boys had
differences between -1 and -2 years, so the distribution clearly was centered
below zero. Since the mean CA for these 12 boys averaged only 7.00 years, the
mean BA-CA of -0.71 suggests a 10% delay.

There are at least two interpretations of these results. One is that ALL
differentially selects children—at least boys—who are developmentally delayed.
As will be seen, this seems unlikely. Moreover, it disagrees with prior findings.
A second interpretation is that the GP2 standards—derived from Midwestern
children primarily from the 1940s—are inappropriate for these children with
ALL because the tempos of growth and progress towards maturation occur at
different (and probably differing) rates.
We supposed that the combination of antimitotic drugs used to treat ALL
(phase “B” in Fig. 17) would discernibly depress the childrens’ tempos of
growth, so that BA-minus-CA would become negative (and become larger
during the course of treatment). In fact, though, there is no evidence of this.
There are several ways to tackle this issue statistically; we chose (1) to group the
HW bone ages into time intervals using age at diagnosis as “time zero” and then
(2) use one-way ANOVA to test for any difference across these intervals. We
were not able to get information on when treatment ceased, so these age
intervals span all ages up to a “catch-all” interval of “over 8 years” after
diagnosis. HW films were not taken at any fixed interval, and the number of
films varied appreciably among patients. The great majority of cases had only
one film, though, so we treated these mixed longitudinal data as if they were
cross-sectional. Analysis was performed separately for boys and girls since it
seemed likely that the tempos of how the GP2 standards relate the childrens’

patterns of HW maturation are at least sex-specific. The results for the subset of
boys are shown in Figure 18. Visually, it is apparent from this graph that
treatment produced no obvious drop in bone age relative to CA.
In Figure 18, the diamond-shaped figure at each time interval defines the
95% confidence limits of the mean, and the middle line in the diamond is the
mean. The grand mean is shown as the light horizontal line across the graph. It
is evident that (1) the diamonds all overlap the grand mean and (2) all of the
groups’ means are close to the grand mean. Consequently, there is no visual
suggestion that the value of BA-CA exhibits any trend across time.
For the girls, indeed, there was a transient rise in the BA-CA values (Fig.
19, between about 0.5 and 2.0 years after diagnosis). This doubtlessly is due to
the predominantly cross-sectional nature of the data since it can hardly be
supposed that treatment is “protective” of bone age.
These visual impressions of “no change” are supported statistically. For
the ANOVA of the females, the df were 9 and 35, F = 0.90 and the P-value was
0.5314. For the males, the df were 9 and 53, with F = 0.35 and the P-value was
0.9519. In this set of data, then, there is no suggestion that the chemotherapeutic
treatment of ALL (with or without irradiation) affected the rate of progression of
HW bone morphologies toward maturity. We had also anticipated that,
following treatment, the children would experience a phase of catch-up growth
(e.g., Caruso-Nicoletti et al. 1993). The depiction of this idea is sketched in
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Fig. 18. Graphical results of examining BA-CA when the data are partitioned
into intervals of time into treatment (data for boys alone). By analysis of
variance, there was no significant difference among the 10 groups. Visually,
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phase “C” of Figure 17. In fact, though, since there was no depression of the rate
of maturation during treatment, there would be no need for a compensatory
phase.
To confirm this, we tested the two “ends” of the data. Specifically, we
tested whether the differences in BA minus CA at the start of treatment (within
1.0 year of diagnosis) was different from that of HW ages more than 6.0 years
after diagnosis. (Again, we could not obtain information on when treatment
ceased, so we used > 6.0 years after diagnosis as a conservative breakpoint.)
In both comparisons (for boys and for girls; Figs. 20, 21), the variability in
BA-CA increased from pre- to posttreatment, but this is fully anticipated because
the children had grown older and variability in this parameter increases with
age (Garn et al. 1958, 1962). Inferentially, there was no difference across time;
BA-CA did not change from soon after diagnosis to several years after treatment.
In girls, the mean of BA-CA was 0.03 years for the set of HW examinations made
within a year of diagnosis and 0.23 years for the set of readings taken more than
6 years after diagnosis. With 1 and 20 df and F = 0.15, the P-value is 0.7033. For
the boys, the mean BA-CA was -0.71 years for the grouping of the examinations
made within a year of diagnosis and -0.47 years for those in excess of 6.0 years
after diagnosis. With 1 and 21 df and F = 0.24, the P-value is 0.6262. There is,
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Fig. 20. Graphical results of examining BA-CA when just the data at the
two extremes of time-in-treatment are compared (data for girls alone). By
analysis of variance, there was no significant difference between the 2 groups.
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Fig. 21. Graphical results of examining BA-CA when just the data at the
two extremes of time-in-treatment are compared (data for boys alone). By
analysis of variance, there was no significant difference between the 2 groups.
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then, no evidence that treatment for ALL had any effect on the progress of HW
bone age towards maturity.
For completeness, we also investigated whether the statistical power of a
repeated-measures design would disclose any effect of treatment on bone age.
We culled the data set for children with at least two HW films that were taken at
least one year apart. Then BA-CA from the earliest film (closest to the diagnosis
of ALL) was compared to BA-CA from the most recent film (when the child had
been in treatment the longest). This resulted in a sample size of 17 pairs of BAs
(sexes combined). There was some apparent change in the mean BA-CA with
time, but the direction of the change was opposite what could be explained by
treatment. Mean BA-CA was 0.43 years at the first examination and 0.16 years at
the most recent examination. At face value, this change suggests that treatment
is protective of bone age, which seems uninterpretible in light of the drugs’
known actions. On the other hand, this change across time is not significant
statistically (t = 1.95; df = 16; P = 0.0693).
This test would seem to be the most likely to find an effect of treatment on
BA if one exists, and the results are negative. Indeed, the trends are not even in
the anticipated direction. In sum, then, there seems to be no suggestion in the
present data set that the tempo of growth as assessed through hand-wrist BA is at
all affected by treatment for ALL.

There is a cautionary note in these results. If one were to ignore the bone
ages from the early films, and, say, only test whether the most recent bone ages
were affected (i.e., those BAs from children who were longest in treatment), the
mean BA-CA is -0.19 (n = 73), which is suggestive that treatment for ALL does
depress the rate of maturation—though not significantly (df = 72; t = 1.54; P =
0.1289). The error in this assumption becomes clear when it is recognized that
the earliest films show that BA is even more “affected” (mean = -0.39 years; t =
2.44; P = 0.0203).
Our contention is that the bone age standards (GP2) produce the observed
BA-CA discrepancies because the tempos of growth are different in the GP2
sample versus how quickly the children with ALL in the present study were
maturing. Treatment for ALL has serious repercussions on the amounts of
growth in the affected children (Kirk et al. 1987; Clayton et al. 1998; Dalton et al.
2003), but it appears to spare the tempo of growth as measured by HW bone age.

CHAPTER V

DISCUSSION

Acute Lymphoblastic Leukemia (ALL) is the most common malignancy of
childhood, constituting approximately 31% of all childhood malignancies
(Niemeyer and Sallan 1998; Berg et al. 2000). While ALL accounts for nearly 75%
of all leukemias in children, it accounts for less than 1% of all adult malignancies
(Perkins et al. 1997; Berg et al. 2000).
ALL strikes children primarily between two and ten years of age, with the
peak age between two and three years. However, it can also attack adolescents
and adults, with a substantial increase around 65 years of age (Berg et al. 2000).
Current statistics from the Surveillance, Epidemiology, and End Results
Program (SEER) reveals that the incidence of ALL in the United States increased
from 2.7 to 3.3 cases per 100,000 children aged 0 to 14 years old during the years
of 1973 to 1995. Each year, around 2,000 to 2,500 new cases of ALL are diagnoses
in the United States (Niemeyer and Sallan 1998).
The cause of ALL is not known, though several explanations for an
overall cause have been explored. Numerous environmental factors have been
examined, including ionizing radiation, the use of drugs and chemicals, as well
as various viruses. Several chemical substances, such as benzene,

chloramphenicol, and phenylbutazone, have been linked to the disease.
Additionally, several viruses have shown associations with leukemia. These
include a statistical linkage of the Epstein-Barr virus with African Burkitt’s
lymphoma, the human T-cell leukemia-lymphoma virus I (HTLV-I) with adult
T-cell leukemia-lymphoma (ATL), and the HTLV-II virus with atypical hairy-cell
leukemia (Perkins et al. 1997).
The overall prognosis of patients with ALL is promising as rates of
remission continue to increase. Survival rates for children are currently near 80
percent, which demonstrate the obvious progress that has been made in the
treatment of ALL (Pui 1999). The current high and improving survival rates of
ALL are due in large part to research efforts and improved treatment strategies
(Goho 1993). When considering the treatment course for a person with ALL, a
number of factors must be considered: the ALL subtype, the comparative
success of previous treatments, levels of leukemic cells in the blood, as well as
the patient’s age and overall health (Wells et al. 1983). Consequently, overall
treatment may vary substantially from person to person.
Various options exist for the treatment of ALL, including chemotherapy,
radiation, and bone marrow transplantation. Physicians may use one therapy
exclusively or combine methods to treat particular cases of ALL. Multimodal
therapy “creates synergistic and additive effects” not normally gained from the
utilization of one therapy only (Goho 1993).

Chemotherapy is the treatment currently chosen for most types of acute
leukemias. Chemotherapeutic agents target DNA replication in cells and strive
to prevent cancer cells from invading, multiplying, metastasizing, and
destroying the host (Skeel and Khleif 2003). While the ultimate mechanisms by
which cancer drugs induce cell death are uncertain, the majority of efficient
cancer agents are believed to either generate chemical lesions in DNA or
interfere with the synthesis of DNA. Destructive mechanisms may range from
apoptosis (programmed cell death) to progression of cell death following mitosis
(Chabner et al. 1999).
While attempting to destroy cancer cells, chemotherapy often affects
normal cells or organs that are undergoing cell reproduction at enhanced rates.
Mucosal linings, such as those of the mouth and intestines, as well as the skin,
hair follicles, and bone marrow, are often affected. The overall goal of a
chemotherapeutic agent, though, is to produce marked destruction of cancer
cells, while providing minimal damage to normal cells of the body (e.g., Skeel
and Khleif 2003). Side effects of chemotherapy may include anemia, nausea,
anaphylaxis, stomatitis, xerostomia, hair loss (alopecia), diarrhea, constipation
and/or an altered nutritional status due to gastrointestinal tract insult (Tipton
2003).
The antimitotic effect and toxicity of the drugs used in the treatment of
ALL are quite apparent from the literature. Therefore, our hypothesis was that

although a person’s overall growth may not be affected by such agents, his/her
tempo of growth could be affected significantly. Adult and adolescent stature
has been shown to be greatly affected by anti-neoplastic treatments, particularly
in combination with irradiation therapy. However, these findings reflected only
changes in a person’s height (and often weight), not a patient’s tempo of growth
as assessed from bone age. In the present study, the question was whether a
patient’s rate of maturation was influenced by such treatment.
Tanner et al. (1975:1) stated,
The concept of physical maturity, while familiar in
general terms, does not suggest immediately a method by
which it can be quantified, let alone measured. Maturity
differs in an important way from a measurement such as
stature, in that the normal growth process takes every
individual from one common condition of being wholly
immature to another of being wholly mature. It thus makes
sense to measure maturity on, say, a percentage basis from 0
to 100. Stature lacks these common end points; a child who
is ‘tall for his age’ may be so because he is more mature than
his coevals, but he may simply be a tall child of average
maturity, which will eventually be a tall adult. Stature and
other ‘size’ measures can thus not be used to define
maturity, except possibly in retrospect when the adult value
is known.
A set of distinct events commonly occurring during growth are needed to
properly define maturity. Examples of such events would be the eruption of a
specific tooth, or (in females) the onset of menarche. One may then assume that
an individual who has undergone a particular event is more mature than
another which has not undergone the event. Furthermore, levels of maturity can

be assessed from “a series of events that always occur in the same sequence from
a single event” (Tanner et al. 1975). Thus, in females, the sequence of breast
development could serve to define a series of three specific events. A female
with fully developed breasts is more mature than a female whose breasts are
developing, and a female whose breasts are developing is more mature than a
female whose breasts have not yet begun to develop. “Events of this kind are
often referred to as developmental ‘milestones’, the name indicating the
intention to define the distance an individual has traveled along the common
road to full maturity” (Tanner et al. 1975:1).
Many series of events exist by which maturation may be measured.
Examples may include eruption of the each tooth in the primary and permanent
dentition as well as initial presentation and ossification of the bones of the hand
and wrist. The difficulty in assessing maturity then becomes how to join the
evidence from many sequences of events, many of which are often invariant
(Tanner et al. 1975).
The best known method of assessing maturity by using the bones of the
hand and wrist complex was developed by Greulich and Pyle in 1959. Their
atlas, which presents a series of “typical” radiographs of children at some 30
points along the maturity scale, allows the user to match a given radiograph as
well as possible to one stage. “The maturity recorded is then given by the age
that characterizes the closest match” (Tanner et al. 1975). Subjectivity of

measurement is obviously a disadvantage of this method; a specific radiograph
will not, more than likely, exactly match one in the atlas series. Furthermore, the
issue of whether to how to measure a radiograph which falls between two in the
atlas is not addressed. Despite these limitations, the Greulich and Pyle method
is used quite often to assess maturity through bone or skeletal age (Tanner et al.
1975).
Average bone or skeletal ages illustrate the maturation status in which
normal children, male and female, attain an established chronological age
(Jimenez-Castellanos et al. 1996). Similar to the growth of organs in the human
body, bones of the skeleton progress through their morphological development
at different age-specific rates in time. In the child, new (secondary) ossification
centers appear over a span of time, and existing ones remodel their
morphologies. Knowing initiation times and morphological changes on bones in
the hand and wrist provide a means of relating skeletal age, or “developmental
age” to chronological age, which is the person’s age in calendar years.
Hand-wrist radiographs are commonly used in the assessment of
biological age because (1) the hand and wrist are reasonably accessible, (2) those
vital organs particularly at risk to radiation damage are not in close proximity,
and (3) there are numerous bones available by which developmental maturity
may be measured. The standards used in this study to which hand-wrist

radiographs were compared were formulated by Greulich and Pyle in 1959, and
are known as the GP2 standards.
The present study involved scoring the 108 hand-wrist films from 73
children (39 boys, 34 girls) who were treated for acute lymphoblastic leukemia at
St. Jude Children’s Research Hospital, Memphis, TN. Mean chronological age at
diagnosis was 4.54 years (sd = 2.81), with a range of 0.10 up to 11.02 years of age.
The number of films per child was highly skewed, because most were taken
soon after the diagnosis of ALL (and, thus, the onset of treatment). Of these 73
children, 53 had just one hand-wrist film.
How large are population differences in the tempos of HW maturation?
In other words, can we anticipate that the GP2 standards—based on Ohio
children growing up in the 1930s and 1940s—are broadly representative of white
childrens’ growth? There have not been many published studies. Mappes et al.
(1992) found no difference in rates of HW development between contemporary
samples of young adolescents from Ohio and Tennessee (though dental ages
differed significantly between the same groups). Loder et al. (1993) and Ontell et
al. (1996) found only modest differences between blacks, whites, and Asian
children growing up in Northern California, except that blacks showed a spurt
in BA at adolescence. Van Rijn et al. (2001) found the GP2 standards to be
appropriate for contemporary Dutch children. Mora et al. (2001) reported (A)
that variability exceeds that of the GP2 standards and (B) that their white sample

from Southern California was delayed during the pubertal interval but then
caught up with the GP2 standards.
Fry (1968) published an insightful comparison of the two commonly used
HW bone age atlases, name the Tanner-Whitehouse norms based on British
children (1959) and the GP2 standards based on mid-American children from
Cleveland, Ohio (Greulich and Pyle 1959). Fry realized that the photographs of
the HW bones at each stage in the GP2 atlas could be scored using the 20 bone
RUS bone-specific method of Tanner and Whitehouse. Fry scored the skeletal
ages of the 25 grades for boys (with CA of 1 through 17 years of age) and the 20
grades for girls (with CA of 1 through 15 years of age).
Data for the boys are plotted in Figure 22, where it is evident that the TW
sample matures significantly faster than the GP2 sample. As shown in the top
graph, the British children were appreciably more mature at most stages than
the Ohio boys. The difference between groups (bottom graph) starts off fairly
small but by stage 10 (3 years of age), the difference is about 1 ½ to 2 years
throughout the rest of the graph. Use of the TW standards would, then
substantially over-estimate the bone age of the ALL children in the present study
and correspondingly under-estimate their amounts of potential growth ahead of
them.
Comparable differences are obtained for the girls (Fig. 23). These
comparisons show that the tempos of growth differ (A) by age (the lines are not
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parallel even accounting for sample fluctuation) and (B) by sex.
Viewing the extent of differences between the TW and GP2 standards
suggest that much smaller differences between the sample of children with ALL
and the GP2 standards in the present study are easily attributable to population
differences in the tempos of maturation.
Several studies utilized stature, as opposed to bone age, to assess
“development” of children treated for ALL. Dalton et al. found a slight decrease
in height in children who received cranial irradiation (2003). This decrease,
however, was not statistically significant when these children were compared to
nonradiated children. Additionally, the means for the z scores at diagnosis for
the sample were +0.22 for height and +0.11 for weight, revealing that, on
average, the sample was slightly taller and heavier than expected according to
United States growth data (Dalton et al. 2003).
Herber et al. (1985) evaluated growth in long term survivors of several
childhood malignancies treated with cranial radiotherapy. Cranial irradiation
“may cause growth hormone deficiency due to disruption of the hypothalamopituitary axis” (Herber et al. 1985:438). Since treatment of malignancies is not
tumor specific and all dividing cells are affected, “there is no reason why the
cells at the epiphyseal plate should be spared, which raises that possibility of
growth retardation during treatment” (Herber et al. 1985:440). However, the
mean of a smaller sample (5 treated with chemotherapy, 10 treated with spinal

irradiation, and 19 treated with cranial irradiation) was 12.12 (sd = 3.93) years as
compared to the mean skeletal age overall at 12.02 (sd = 3.82) years. In addition,
bone age was retarded by no more than 18 months in any patient. These results
indicated that bone age was affected only slightly if at all. The majority of
children in the study who received cranial irradiation had been diagnosed with
acute lymphoblastic leukemia. Additionally, previous reports have suggested
that children diagnosed with ALL are taller than average at diagnostic
presentation (Griffin and Wadsworth 1980; Broomhall et al. 1983).
Kirk et al. (1987) reported high rates of diminished stature in children
treated for ALL. However, overall growth retardation was not shown. Stature
had decreased by more than one standard deviation in 32 percent of survivors at
4 years post-diagnosis and in 71 percent at 6 years post-diagnosis. Standard
deviation scores were constructed as standard deviation scores from the
population mean. Kirk et al. (1987) also mentioned growth of younger children
and those children especially tall for their age at diagnosis were more
susceptible to reductions in overall stature.
Birkebaek and Clausen (1998) evaluated height and weight patterns in
children up to 20 years after treatment for ALL. Their results disclosed similar
height deviation scores at diagnosis and at follow-up; however, there was a
significant decrease in scores during treatment. As was similar to
aforementioned studies, the sample of children with ALL evaluated was

significantly taller at the time of diagnosis when compared with the normal
population. “Whether the coexistence of ALL and a high growth rate is
incidental or the result of a common factor is not known” (Birkebaek and
Clausen 1998:163).
Though several of the aforementioned studies noted an overall decrease
in stature, bone age or the tempo of growth has not been shown to be adversely
affected by chemotherapy and/or radiation. That is, chronological age (CA) in
children treated for ALL was essentially equal to bone age (BA). This finding is
optimistic in that it signifies that growth in children with ALL is not
compromised, as one might assume. It is important to note that a long-term or
permanent decrease in final adult stature was not seen unless (1) the patient
sustained irreversible damage to the hypothalamic-pituitary axis, which in turn
adversely affected the production and release of essential growth hormones
and/or (2) the patient was so young that critical endocrinological changes were
not expressed (Lawrence et al. 1971).
Statistical analysis revealed a desirable situation. We analyzed the data
using analysis of variance, having partitioned the HW bone ages into intervals
based on how long past the onset of treatment the examination was made, which
is concomitantly, the age at diagnosis. The data for boys (Fig. 18) showed that
the HW films taken within one year of diagnosis exhibited a developmental
delay (mean BA-CA of -0.71 years), but the subsequent films showed a gradual

diminution in the size of BA-CA such that (1) only the first age interval showed
a significant delay in HW bone age and (2) BA-CA improved over time. It
seemed parsimonious to assume that the initial discrepancy (a 10% delay in BA
compared to CA) because these children’s tempo of growth (irrespective of ALL)
differed from the tempo of children used to develop the GP2 standards.
Alternatively, it could be argued from these results that (1) in boys (but not in
girls) ALL delays growth, so BA-CA is significant at the start of treatment and
(2) the potent antimitotic drugs used to treat the disease is somehow protective
such that BA-CA diminishes towards zero during and after treatment. This
interpretation flies in the face of several known iatrogenic consequences of
chemotherapeutic treatment, and this interpretation is not supported by the few
other studies of HW bone age in children treated for ALL (Tamminga et al. 1993).
Moreover, the girls in the present sample show a simpler pattern (Fig. 19).
Mean BA-CA is very close to zero at the start of treatment and remains there —
there is no statistical evidence that treatment has any effect on BA-CA.
These data can be expressed in another fashion to affirm these earlier
tests. Here we forego the categorization of cases into intervals after diagnosis
and simply plot BA-CA against time in treatment (Fig. 24). The linear regression
lines, calculated by sex, both begin slightly below zero but have positive slopes.
For boys, the Y intercept, which is the status at diagnosis, shows that BA-CA
starts off negative (intercept = -0.66; t = 3.3; P = 0.0018), but BA-CA diminishes
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insignificantly with time (b = +0.05; t = 1.0; P = 0.3062).
For girls, there is no evidence of the initial depression in BA seen for boys;
the Y intercept is -0.08, which is not significantly different from zero (t = 0.3; P =
0.7979). The slope of the line fit to the data for girls is statistically
indistinguishable from a horizontal line, meaning that there is no delay at
diagnosis, nor does treatment have any discernible effect on the tempo of HW
bone maturation. In sum, these results wholly duplicate those describe before,
but use a different method of assessment to confirm the results.
It is simpler to invoke sampling fluctuation (i.e., a nonrepresentative
sampling of boys early in treatment) to explain the observed BA-CA depression
and/or a different tempo of growth in the GP2 standards than to accept that BACA depression is biologically important. These conjectures can be solved with
replication of this study using different children who have been treated for ALL.

CHAPTER VI

SUMMARY AND CONCLUSIONS

Acute Lymphoblastic Leukemia (ALL) constitutes the most common
malignancy of childhood, consisting of 31 percent of all childhood malignancies.
ALL primarily strikes children between primarily two and ten years of age, but
may occur in adolescents and adults. Treatment strategies to target the disease
include individual or combination therapy with chemotherapeutic agents,
irradiation of the neck and/or spine, and, occasionally, bone marrow
transplantation. The aggressive nature of anti-neoplastic therapies often results
in numerous craniofacial and dental sequelae as well as additional iatrogenic
effects on the entire body. Cranial irradiation may adversely affect the
hypothalamic-pituitary axis, resulting in a decrease in growth hormone
production. Children with ALL may experience a transient reduction in stature
coincident with therapy, and the risk of permanent size diminution increases
greatly if treatment includes cranial irradiation.
The present study used hand-wrist radiographs to determine the
maturational status of children treated for ALL. We anticipated that antineoplastic therapies would influence a child’s bone development and thus
children in our sample would show delayed bone development.

Hand-wrist (HW) radiographs of 73 children (39 boys, 34 girls) treated at
St. Jude Children’s Research Hospital for ALL were evaluated to assess HW
bone age. Mean chronological age at diagnosis was 4.54 years (sd = 2.81). Bone
ages were scored using Greulich and Pyle’s 1959 atlas method.
We supposed that the combination of antimitotic drugs used to treat ALL
would discernibly depress the childrens’ tempos of growth, so that BA-CA (bone
age minus chronological age) would be negative. Instead, the data showed no
evidence of any effect. In fact, since there was no depression of the rate of
maturation during treatment, there was no need for a compensatory, or “catchup,” phase. There is no evidence in this study that treatment for ALL has any
effect on the progress of hand-wrist morphological bone age. Treatment for ALL
spares the tempo of growth as assessed by HW bone age.
This finding is quite favorable from the standpoint of the child’s overall
health, as well as for orthodontic treatment. Orthodontics frequently harnesses a
child’s growth potential or “growth spurt” to improve the treatment outcome.
Certain Class II or Class III malocclusions may be corrected in young children
through orthodontic techniques that maximize the child’s growth potential.
Such examples might include treating a Class II malocclusion with a facebow
headgear to the maxillary molars. The headgear serves to constrain the maxilla,
while allowing the mandible to grow forward. Knowing that the growth
potential of children treated for ALL is not hindered or delayed ensures these

children may be treated orthodontically as normal individuals with normal
growth spurts. Orthodontic treatment in these children, however, must always
be in cooperation with and under the approval of the supervising oncologist or
physician. Communication between the oncologist, dentist and orthodontist, as
well as any additional physicians, may guarantee that the child’s overall health
is best managed.
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APPENDIX

Appendix

Individual plots of hand-wrist bone age against chronological age for
the 73 children with ALL in this study
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Fig. A-1. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1056). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-2. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1036). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-3. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1020). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-4. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1039). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-5. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1029). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-6. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1059). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-7. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1003). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-8. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1030). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-9. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1007). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-10. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1052). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-11. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1024). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-12. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1047). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-13. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1010). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-14. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1025). The square symbol denotes age at
diagnosis of ALL.

14

12
B

Bone Age

10

J

8

6

4

2

0
0

2

4

6
8
Chronological Age

10

12

14

Fig. A-15. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1032). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-16. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1013). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-17. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1038). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-18. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1040). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-19. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1018). The square symbol denotes age at
diagnosis of ALL.

14

12

J
J

Bone Age

10

J
B

8

6

4

2

0
0

2

4

6
8
Chronological Age

10

12

14

Fig. A-20. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1055). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-21. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1033). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-22. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1065). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-23. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1008). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-24. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1058). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-25. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1071). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-26. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1041). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-27. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1066). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-28. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1012). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-29. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1045). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-30. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1063). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-31. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1019). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-32. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1022). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-33. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1068). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-34. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1061). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-35. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1017). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-36. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1043). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-37. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1062). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-38. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1054). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-39. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1051). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-40. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1031). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-41. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1034). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-42. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1069). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-43. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1027). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-44. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1006). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-45. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1023). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-46. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1057). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-47. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1072). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-48. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1028). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-49. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1009). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-50. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1064). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-51. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1015). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-52. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1050). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-53. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1001). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-54. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1021). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-55. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1011). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-56. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1067). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-57. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1000). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-58. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1016). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-59. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1004). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-60. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1026). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-61. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1048). The square symbol denotes age at
diagnosis of ALL.

14

12
J
10

Bone Age

B
8

6

4

2

0
0

2

4

6
8
Chronological Age

10

12

14

Fig. A-62. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1042). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-63. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1049). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-64. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1044). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-65. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1014). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-66. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1046). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-67. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1060). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-68. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1070). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-69. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1002). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-70. Plot of chronological age against GP2 bone age (circle) for a
boy (pseudo-record #1053). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-71. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1037). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-72. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1005). The square symbol denotes age at
diagnosis of ALL.
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Fig. A-73. Plot of chronological age against GP2 bone age (circle) for a
girl (pseudo-record #1035). The square symbol denotes age at
diagnosis of ALL.

VITA

Mary Elizabeth Martin was born in Norfolk, Virginia, on August
15, 1977 where her father, John Martin, was stationed with the United
States Navy. Her family moved to Middle Tennessee when she was six
months old and resided briefly with her paternal grandparents in
Springfield, Tennessee. Her family eventually settled in Hendersonville,
Tennessee where she graduated from Hendersonville High School in May
of 1995. Mary Beth attended The University of Tennessee at Knoxville
where she majored in Biology and received a Bachelor of Science degree in
May of 1999. She received her dental training and a Doctor of Dental
Surgery degree from The University of Tennessee at Memphis in May of
2003. In August of 2003, she entered The University of Tennessee’s
Orthodontic program. She is expected to receive a Master of Dental
Science degree in May 2006. Following graduation, Mary Beth will join
her husband, David, to live in Jonesboro, Arkansas.
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